

STATISTICAL COMPENDIUM: MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT IN 2002 ARKANSAS

LIST OF TABLES

OVERVIEW OF STUDY POPULATION

TABLE 1. OVERVIEW OF BENEFICIARY SELECTION CRITERIA FOR STUDY POPULATION

FOR ALL MEDICAID BENEFICIARIES

TABLE 2. CHARACTERISTICS OF MEDICAID STUDY POPULATION BENEFICIARIES, BY BASIS OF ELIGIBILITY

TABLE 3. MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT PER BENEFICIARY, BY BENEFICIARY CHARACTERISTIC

TABLE 4. MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT PER BENEFIT MONTH, BY BENEFICIARY CHARACTERISTIC

TABLE 5. MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT PER BENEFIT MONTH, BY BRAND STATUS AND BENEFICIARY CHARACTERISTIC

TABLE 6. MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT, BY BRAND STATUS AND THERAPEUTIC CATEGORY

TABLE 7. MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT, BY TOP 10 DRUG GROUP

FOR ALL NONDUAL BENEFICIARIES

TABLE ND.2. CHARACTERISTICS OF MEDICAID STUDY POPULATION BENEFICIARIES, BY BASIS OF ELIGIBILITY

TABLE ND.3. MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT PER BENEFICIARY, BY BENEFICIARY CHARACTERISTIC

TABLE ND.4. MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT PER BENEFIT MONTH, BY BENEFICIARY CHARACTERISTIC

TABLE ND.5. MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT PER BENEFIT MONTH, BY BRAND STATUS AND BENEFICIARY CHARACTERISTIC

TABLE ND.6. MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT, BY BRAND STATUS AND THERAPEUTIC CATEGORY

TABLE ND.7-7D. MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT, BY TOP 10 DRUG GROUP

TABLE ND.8. MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT FOR ALL-YEAR NURSING FACILITY RESIDENTS, BY BENEFICIARY CHARACTERISTIC

TABLE ND.9. MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT FOR ALL-YEAR NURSING FACILITY RESIDENTS, BY BRAND STATUS AND THERAPEUTIC CATEGORY

TABLE ND.10-10D. MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT FOR TOP 10 DRUG GROUPS AMONG ALL-YEAR NURSING FACILITY RESIDENTS, BY TOP 10 DRUG GROUP

TABLE ND.11. USE AND REIMBURSEMENT FOR DRUGS EXCLUDED BY STATUTE FROM MEDICARE PART D AMONG NONDUALS, BY BENEFICIARY CHARACTERISTIC

TABLE ND.12. USE AND REIMBURSEMENT FOR DRUGS EXCLUDED BY STATUTE FROM MEDICARE PART D AMONG NONDUALS PER BENEFIT MONTH, BY BENEFICIARY CHARACTERISTIC

TABLE ND.13. USE AND REIMBURSEMENT FOR DRUGS EXCLUDED BY STATUTE FROM MEDICARE PART D FOR SELECTED DRUG CATEGORIES AMONG NONDUALS

FOR DUAL ELIGIBLE BENEFICIARIES

- TABLE D.2. CHARACTERISTICS OF MEDICAID STUDY POPULATION BENEFICIARIES, BY BASIS OF ELIGIBILITY
- TABLE D.3. MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT PER BENEFICIARY, BY BENEFICIARY CHARACTERISTIC
- TABLE D.4. MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT PER BENEFIT MONTH, BY BENEFICIARY CHARACTERISTIC
- TABLE D.5. MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT PER BENEFIT MONTH, BY BRAND STATUS AND BENEFICIARY CHARACTERISTIC
- TABLE D.6. MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT, BY BRAND STATUS AND THERAPEUTIC CATEGORY
- TABLE D.7-7D. MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT, BY TOP 10 DRUG GROUP
- TABLE D.8. MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT FOR ALL-YEAR NURSING FACILITY RESIDENTS, BY BENEFICIARY CHARACTERISTIC
- TABLE D.9. MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT FOR ALL-YEAR NURSING FACILITY RESIDENTS, BY BRAND STATUS AND THERAPEUTIC CATEGORY
- TABLE D.10-10D. MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT FOR TOP 10 DRUG GROUPS AMONG ALL-YEAR NURSING FACILITY RESIDENTS, BY TOP 10 DRUG GROUP
- TABLE D.11. USE AND REIMBURSEMENT FOR DRUGS EXCLUDED BY STATUTE FROM MEDICARE PART D AMONG DUALS, BY BENEFICIARY CHARACTERISTIC
- TABLE D.12. USE AND REIMBURSEMENT FOR DRUGS EXCLUDED BY STATUTE FROM MEDICARE PART D AMONG DUALS PER BENEFIT MONTH, BY BENEFICIARY CHARACTERISTIC
- TABLE D.13. USE AND REIMBURSEMENT FOR DRUGS EXCLUDED BY STATUTE FROM MEDICARE PART D FOR SELECTED DRUG CATEGORIES AMONG DUALS

SUPPLEMENTAL TABLES

- SUPPLEMENTAL TABLE 1. MEDICAID PHARMACY REIMBURSEMENT FOR DUAL ELIGIBLE BENEFICIARIES
- SUPPLEMENTAL TABLE 1A. MEDICAID PHARMACY REIMBURSEMENT FOR DISABLED DUAL ELIGIBLE BENEFICIARIES UNDER AGE 65
- SUPPLEMENTAL TABLE 1B. MEDICAID PHARMACY REIMBURSEMENT FOR DUAL ELIGIBLE BENEFICIARIES AGE 65 AND OLDER
- SUPPLEMENTAL TABLE 1C. MEDICAID PHARMACY REIMBURSEMENT FOR DUAL ELIGIBLE BENEFICIARIES AGE 65 TO 74
- SUPPLEMENTAL TABLE 1D. MEDICAID PHARMACY REIMBURSEMENT FOR DUAL ELIGIBLE BENEFICIARIES AGE 75 TO 84
- SUPPLEMENTAL TABLE 1E. MEDICAID PHARMACY REIMBURSEMENT FOR DUAL ELIGIBLE BENEFICIARIES AGE 85 AND OLDER

APPENDIX TABLE

- APPENDIX TABLE A.1. CHARACTERISTICS OF MEDICAID BENEFICIARIES WITH AT LEAST ONE MONTH OF PHARMACY BENEFIT COVERAGE, BY BASIS OF ELIGIBILITY, NONDUAL BENEFICIARIES
- APPENDIX TABLE A.2. MEDICAID BENEFICIARIES AND THEIR BENEFIT MONTHS WITH OR WITHOUT FEE-FOR-SERVICE PHARMACY BENEFITS, NONDUAL BENEFICIARIES
- APPENDIX TABLE A.3. CHARACTERISTICS OF MEDICAID BENEFICIARIES WITH AT LEAST ONE MONTH OF PHARMACY BENEFIT COVERAGE, BY BASIS OF ELIGIBILITY, DUAL ELIGIBLE BENEFICIARIES
- APPENDIX TABLE A.4. MEDICAID BENEFICIARIES AND THEIR BENEFIT MONTHS WITH OR WITHOUT FEE-FOR-SERVICE PHARMACY BENEFITS, DUAL ELIGIBLE BENEFICIARIES

TABLE ND.2
 CHARACTERISTICS OF MEDICAID STUDY POPULATION BENEFICIARIES, BY BASIS OF ELIGIBILITY^{a,b}
 NONDUAL BENEFICIARIES, ARKANSAS, 2002

| Beneficiary Characteristics | No. of Benes | | | | | | | No. of Bene Mos | | | | | | | | | | | |
|----------------------------------------------|----------------|--------------|---------------|----------------|----------------|-------------------|------------------|-----------------|----------------|------------------|------------------|-------------------|------------------|---------------|----------------|------------------|------------------|-------------------|---|
| | All | Aged | Disabled | Adults | Children | Other/ Unknown | All | Aged | Disabled | Adults | Children | Other/ Unknown | All | Aged | Disabled | Adults | Children | Other/ Unknown | |
| All | 547,829 | 3,268 | 71,634 | 144,972 | 327,955 | 0 | 5,137,141 | 31,530 | 700,752 | 1,374,779 | 3,030,080 | 0 | 5,137,141 | 31,530 | 700,752 | 1,374,779 | 3,030,080 | 0 | |
| Age | | | | | | | | | | | | | | | | | | | |
| 5 and younger | 138,293 | 0 | 5,686 | 71 | 132,536 | 0 | 1,221,941 | 0 | 56,356 | 508 | 1,165,077 | 0 | 1,221,941 | 0 | 56,356 | 508 | 1,165,077 | 0 | |
| 6-14 | 160,648 | 0 | 11,735 | 197 | 148,716 | 0 | 1,561,255 | 0 | 125,173 | 1,489 | 1,434,593 | 0 | 1,561,255 | 0 | 125,173 | 1,489 | 1,434,593 | 0 | |
| 15-20 | 87,551 | 0 | 7,674 | 33,582 | 46,295 | 0 | 810,801 | 0 | 79,905 | 301,803 | 429,093 | 0 | 810,801 | 0 | 79,905 | 301,803 | 429,093 | 0 | |
| 21-44 | 129,660 | 0 | 21,693 | 107,573 | 394 | 0 | 1,252,858 | 0 | 210,049 | 1,041,537 | 1,272 | 0 | 1,252,858 | 0 | 210,049 | 1,041,537 | 1,272 | 0 | |
| 45-64 | 26,735 | 0 | 23,196 | 3,537 | 2 | 0 | 240,301 | 0 | 210,911 | 29,373 | 17 | 0 | 240,301 | 0 | 210,911 | 29,373 | 17 | 0 | |
| 65-74 | 1,915 | 758 | 1,148 | 9 | 0 | 0 | 19,743 | 6,968 | 12,733 | 42 | 0 | 0 | 19,743 | 6,968 | 12,733 | 42 | 0 | 0 | |
| 75-84 | 1,464 | 1,109 | 353 | 2 | 0 | 0 | 14,488 | 10,554 | 3,910 | 24 | 0 | 0 | 14,488 | 10,554 | 3,910 | 24 | 0 | 0 | |
| 85 and older | 1,551 | 1,401 | 149 | 1 | 0 | 0 | 15,726 | 14,008 | 1,715 | 3 | 0 | 0 | 15,726 | 14,008 | 1,715 | 3 | 0 | 0 | |
| Unknown | 12 | 0 | 0 | 0 | 12 | 0 | 28 | 0 | 0 | 0 | 28 | 0 | 28 | 0 | 0 | 0 | 28 | 0 | |
| Gender | | | | | | | | | | | | | | | | | | | |
| Female | 338,054 | 2,151 | 36,619 | 137,732 | 161,552 | 0 | 3,220,013 | 20,968 | 365,894 | 1,323,098 | 1,510,053 | 0 | 3,220,013 | 20,968 | 365,894 | 1,323,098 | 1,510,053 | 0 | |
| Male | 209,095 | 1,087 | 34,980 | 7,176 | 165,852 | 0 | 1,911,787 | 10,297 | 334,570 | 51,293 | 1,515,627 | 0 | 1,911,787 | 10,297 | 334,570 | 51,293 | 1,515,627 | 0 | |
| Unknown | 680 | 30 | 35 | 64 | 551 | 0 | 5,341 | 265 | 288 | 388 | 4,400 | 0 | 5,341 | 265 | 288 | 388 | 4,400 | 0 | |
| Race | | | | | | | | | | | | | | | | | | | |
| White | 333,435 | 2,000 | 39,655 | 94,653 | 197,127 | 0 | 3,134,948 | 18,961 | 382,072 | 909,129 | 1,824,786 | 0 | 3,134,948 | 18,961 | 382,072 | 909,129 | 1,824,786 | 0 | |
| African American | 178,657 | 984 | 23,211 | 46,003 | 108,459 | 0 | 1,690,626 | 9,632 | 236,648 | 432,635 | 1,011,711 | 0 | 1,690,626 | 9,632 | 236,648 | 432,635 | 1,011,711 | 0 | |
| Other/unknown | 35,737 | 284 | 8,768 | 4,316 | 22,369 | 0 | 311,567 | 2,937 | 82,032 | 33,015 | 193,583 | 0 | 311,567 | 2,937 | 82,032 | 33,015 | 193,583 | 0 | |
| Use of Nursing Facilities^c | | | | | | | | | | | | | | | | | | | |
| Entire year | 1,372 | 600 | 772 | 0 | 0 | 0 | 13,855 | 5,829 | 8,026 | 0 | 0 | 0 | 13,855 | 5,829 | 8,026 | 0 | 0 | 0 | |
| Part year | 515 | 175 | 338 | 2 | 0 | 0 | 4,892 | 1,526 | 3,351 | 15 | 0 | 0 | 4,892 | 1,526 | 3,351 | 15 | 0 | 0 | |
| None | 545,942 | 2,493 | 70,524 | 144,970 | 327,955 | 0 | 5,118,394 | 24,175 | 689,375 | 1,374,764 | 3,030,080 | 0 | 5,118,394 | 24,175 | 689,375 | 1,374,764 | 3,030,080 | 0 | |
| Maintenance Assistance Status | | | | | | | | | | | | | | | | | | | |
| Cash | 123,261 | 1,373 | 63,363 | 20,766 | 37,759 | 0 | 1,172,881 | 15,634 | 633,773 | 171,557 | 351,917 | 0 | 1,172,881 | 15,634 | 633,773 | 171,557 | 351,917 | 0 | |
| Medically needy | 9,919 | 113 | 2,314 | 4,869 | 2,623 | 0 | 53,094 | 397 | 9,046 | 24,293 | 19,358 | 0 | 53,094 | 397 | 9,046 | 24,293 | 19,358 | 0 | |
| Poverty-related | 229,791 | 136 | 542 | 28,271 | 200,842 | 0 | 2,045,655 | 974 | 4,223 | 198,041 | 1,842,417 | 0 | 2,045,655 | 974 | 4,223 | 198,041 | 1,842,417 | 0 | |
| Other/unknown | 184,858 | 1,646 | 5,415 | 91,066 | 86,731 | 0 | 1,865,511 | 14,525 | 53,710 | 980,888 | 816,388 | 0 | 1,865,511 | 14,525 | 53,710 | 980,888 | 816,388 | 0 | |
| Managed Care Status | | | | | | | | | | | | | | | | | | | |
| FFS all year | 547,829 | 3,288 | 71,634 | 144,972 | 327,955 | 0 | 5,137,141 | 31,530 | 700,752 | 1,374,779 | 3,030,080 | 0 | 5,137,141 | 31,530 | 700,752 | 1,374,779 | 3,030,080 | 0 | |
| FFS part year, with Rx claims | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| FFS part year, no Rx claims | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |

Table ND2

Nondual Beneficiaries

Source: Data for this table are from the MAX 2002 file for Arkansas, released by CMS in 05/2006. This table was produced on 04/19/2007.

- a. Table ND.2 includes the beneficiaries represented by Cell K of Table 1. Benefit months are months during which beneficiaries had fee-for-service pharmacy benefits.
- b. Medicaid basis of eligibility is classified as: aged, disabled, adults, and children. The disabled group includes beneficiaries of any age who were determined to be eligible because of disability or blindness. The children's group includes children receiving foster care and adoptive services. The total includes some beneficiaries with unknown basis of eligibility and some whose age categories are not consistent with basis of eligibility.
- c. Please refer to footnote f of Table 1 for methodology used to determine nursing facility residence.

Bene(s) = beneficiary (or beneficiaries); Bene Mo(s) = benefit month(s); CMS = Center for Medicare and Medicaid Services; FFS = fee-for-service pharmacy benefit; MAX = Medicaid Analytic Extract; Rx = pharmacy benefit.

TABLE ND.3

MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT PER BENEFICIARY, BY BENEFICIARY CHARACTERISTIC^{a,b}
 NONDUAL BENEFICIARIES, ARKANSAS, 2002

| Beneficiary Characteristics | % with at Least One Rx | Mean No. of Rx | Mean Rx \$ | \$ per Rx | Mean \$, All Services | Rx \$ as % of All Services | No. of Benes |
|----------------------------------------------|------------------------|----------------|------------|-----------|-----------------------|----------------------------|--------------|
| All | 56.3 % | 5.5 | \$290 | \$53 | \$2,205 | 13.2 % | 547,829 |
| Age | | | | | | | |
| 5 and younger | 70.2 | 5.0 | 183 | 37 | 2,226 | 8.2 | 138,293 |
| 6-14 | 61.4 | 4.7 | 256 | 55 | 1,622 | 15.8 | 160,648 |
| 15-20 | 50.1 | 4.1 | 229 | 56 | 2,132 | 10.8 | 87,551 |
| 21-44 | 36.9 | 4.3 | 266 | 62 | 1,930 | 13.8 | 129,660 |
| 45-64 | 69.3 | 21.3 | 1,248 | 59 | 6,300 | 19.8 | 26,735 |
| 65-74 | 58.9 | 22.1 | 1,101 | 50 | 6,696 | 16.4 | 1,915 |
| 75-84 | 47.1 | 20.7 | 975 | 47 | 7,864 | 12.4 | 1,464 |
| 85 and older | 30.2 | 13.5 | 598 | 44 | 6,467 | 9.2 | 1,551 |
| Unknown | 0.0 | 0.0 | 0 | 0 | 4 | 0.0 | 12 |
| Basis of Eligibility^c | | | | | | | |
| Aged | 46.9 | 20.3 | 948 | 47 | 8,240 | 11.5 | 3,268 |
| Disabled | 71.7 | 17.1 | 1,253 | 73 | 8,387 | 14.9 | 71,634 |
| Adults | 32.2 | 2.4 | 88 | 37 | 880 | 10.0 | 144,972 |
| Children | 63.6 | 4.2 | 163 | 39 | 1,381 | 11.8 | 327,955 |
| Unknown | 0.0 | 0.0 | 0 | 0 | 0 | 0.0 | 0 |
| Gender | | | | | | | |
| Female | 52.1 | 5.3 | 253 | 48 | 1,861 | 13.6 | 338,054 |
| Male | 63.0 | 5.9 | 350 | 59 | 2,760 | 12.7 | 209,095 |
| Unknown | 54.3 | 5.4 | 261 | 49 | 2,585 | 10.1 | 680 |
| Race | | | | | | | |
| White | 57.9 | 5.9 | 317 | 53 | 2,207 | 14.4 | 333,435 |
| African American | 53.5 | 4.6 | 221 | 48 | 2,006 | 11.0 | 178,657 |
| Other/unknown | 55.1 | 6.0 | 382 | 63 | 3,187 | 12.0 | 35,737 |
| Use of Nursing Facilities^d | | | | | | | |
| Entire year | 92.3 | 63.0 | 3,428 | 54 | 35,705 | 9.6 | 1,372 |
| Part year | 93.8 | 44.7 | 2,626 | 59 | 26,728 | 9.8 | 515 |
| None | 56.1 | 5.3 | 280 | 53 | 2,098 | 13.3 | 545,942 |
| Maintenance Assistance Status | | | | | | | |
| Cash | 67.1 | 11.5 | 745 | 65 | 4,853 | 15.4 | 123,261 |
| Medically needy | 52.5 | 4.9 | 287 | 58 | 3,252 | 8.8 | 9,919 |
| Poverty related | 64.5 | 4.2 | 155 | 37 | 1,472 | 10.5 | 229,791 |
| Other/unknown | 39.1 | 3.2 | 155 | 49 | 1,295 | 11.9 | 184,858 |

Source: Data for this table are from the MAX 2002 file for Arkansas, released by CMS in 05/2006. This table was produced on 04/19/2007.

- a. Table ND.3 includes beneficiaries represented by Cell K of Table 1.
 - b. The Medicaid reimbursement amounts presented in this table do not reflect federally required rebates from drug manufacturers to the state.
 - c. Medicaid basis of eligibility is classified as: aged, disabled, adults, and children. The disabled group includes beneficiaries of any age who were determined to be eligible because of disability or blindness. The children's group includes children receiving foster care and adoptive services.
 - d. Please refer to footnote f of Table 1 for methodology used to determine nursing facility residence.
- Bene(s) = beneficiary (or beneficiaries); CMS = Center for Medicare and Medicaid Services; MAX = Medicaid Analytic Extract; OTC = over-the-counter; Rx = prescription(s) or pharmacy benefit; \$ = Medicaid reimbursement.

TABLE ND.4
 MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT PER BENEFIT MONTH, BY BENEFICIARY CHARACTERISTIC^{a,b}
 NONDUAL BENEFICIARIES, ARKANSAS, 2002

| Beneficiary Characteristics | Mean No. of Rx | Mean Rx \$ | Rx \$ as % of All Services | No. of Rx, % with: | | | | | Mean \$, All Services | Benes | Bene Mos | |
|----------------------------------------------|----------------|------------|----------------------------|--------------------|----------------------------|----------------------------|----------------------------|-----------------------------|-----------------------|-------|----------|--------------|
| | | | | None | More than 0, but 1 or Less | More than 1, but 2 or Less | More than 2, but 5 or Less | More than 5, but 10 or Less | | | | More than 10 |
| All | 0.6 | \$31 | 13.2 % | 43.7 % | 45.7 % | 5.4 % | 4.3 % | 0.8 % | 0.1 % | \$235 | 547,829 | 5,137,141 |
| Age | | | | | | | | | | | | |
| 5 and younger | 0.6 | 21 | 8.2 | 29.8 | 62.0 | 6.0 | 2.1 | 0.2 | 0.0 | 252 | 138,293 | 1,221,941 |
| 6-14 | 0.5 | 26 | 15.8 | 38.6 | 54.0 | 4.5 | 2.6 | 0.3 | 0.0 | 167 | 160,648 | 1,561,255 |
| 15-20 | 0.4 | 25 | 10.8 | 49.9 | 43.0 | 4.2 | 2.4 | 0.4 | 0.0 | 230 | 87,551 | 810,801 |
| 21-44 | 0.4 | 28 | 13.8 | 63.1 | 26.8 | 5.1 | 4.5 | 0.5 | 0.0 | 200 | 129,660 | 1,252,858 |
| 45-64 | 2.4 | 139 | 19.8 | 30.7 | 18.9 | 13.6 | 28.4 | 7.9 | 0.5 | 701 | 26,735 | 240,301 |
| 65-74 | 2.1 | 107 | 16.4 | 41.1 | 13.4 | 9.7 | 25.7 | 8.7 | 1.4 | 650 | 1,915 | 19,743 |
| 75-84 | 2.1 | 99 | 12.4 | 52.9 | 8.1 | 7.2 | 18.4 | 11.0 | 2.5 | 795 | 1,464 | 14,488 |
| 85 and older | 1.3 | 59 | 9.2 | 69.8 | 3.9 | 3.2 | 13.9 | 8.0 | 1.2 | 638 | 1,551 | 15,726 |
| Unknown | 0.0 | 0 | 0.0 | 100.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 2 | 12 | 28 |
| Basis of Eligibility^c | | | | | | | | | | | | |
| Aged | 2.1 | 98 | 11.5 | 53.1 | 7.8 | 6.8 | 18.9 | 11.1 | 2.3 | 854 | 3,268 | 31,530 |
| Disabled | 1.8 | 128 | 14.9 | 28.3 | 32.5 | 13.4 | 20.7 | 4.8 | 0.3 | 857 | 71,634 | 700,752 |
| Adults | 0.3 | 9 | 10.0 | 67.8 | 27.2 | 3.3 | 1.7 | 0.1 | 0.0 | 93 | 144,972 | 1,374,779 |
| Children | 0.5 | 18 | 11.8 | 36.4 | 57.2 | 4.6 | 1.8 | 0.1 | 0.0 | 149 | 327,955 | 3,030,080 |
| Unknown | 0.0 | 0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0 | 0 | 0 |
| Gender | | | | | | | | | | | | |
| Female | 0.6 | 27 | 13.6 | 47.9 | 42.0 | 5.0 | 4.2 | 0.8 | 0.1 | 195 | 338,054 | 3,220,013 |
| Male | 0.6 | 38 | 12.7 | 37.0 | 51.6 | 6.1 | 4.5 | 0.7 | 0.1 | 302 | 209,095 | 1,911,787 |
| Unknown | 0.7 | 33 | 10.1 | 45.7 | 44.1 | 4.6 | 3.7 | 1.8 | 0.1 | 329 | 680 | 5,341 |
| Race | | | | | | | | | | | | |
| White | 0.6 | 34 | 14.4 | 42.1 | 46.2 | 5.9 | 4.8 | 0.9 | 0.1 | 235 | 333,435 | 3,134,948 |
| African American | 0.5 | 23 | 11.0 | 46.5 | 45.2 | 4.6 | 3.2 | 0.4 | 0.0 | 212 | 178,657 | 1,690,626 |
| Other/unknown | 0.7 | 44 | 12.0 | 44.9 | 43.2 | 5.4 | 5.3 | 1.1 | 0.1 | 366 | 35,737 | 311,567 |
| Use of Nursing Facilities^d | | | | | | | | | | | | |
| Entire year | 6.2 | 340 | 9.6 | 7.7 | 5.7 | 6.0 | 28.2 | 37.8 | 14.6 | 3,536 | 1,372 | 13,855 |
| Part year | 4.7 | 276 | 9.8 | 6.2 | 10.5 | 12.2 | 38.3 | 27.0 | 5.8 | 2,814 | 515 | 4,892 |
| None | 0.6 | 30 | 13.3 | 43.9 | 45.8 | 5.4 | 4.2 | 0.6 | 0.0 | 224 | 545,942 | 5,118,394 |
| Maintenance Assistance Status | | | | | | | | | | | | |
| Cash | 1.2 | 78 | 15.4 | 32.9 | 41.5 | 10.2 | 12.7 | 2.6 | 0.1 | 510 | 123,261 | 1,172,881 |
| Medically needy | 0.9 | 54 | 8.8 | 47.5 | 30.0 | 11.1 | 10.7 | 0.8 | 0.0 | 608 | 9,919 | 53,094 |
| Poverty related | 0.5 | 17 | 10.5 | 35.5 | 57.8 | 4.9 | 1.7 | 0.1 | 0.0 | 165 | 229,791 | 2,045,655 |
| Other/unknown | 0.3 | 15 | 11.9 | 60.9 | 34.3 | 2.6 | 1.7 | 0.4 | 0.1 | 128 | 184,858 | 1,865,511 |

Table ND4

Nondual Beneficiaries

Source: Data for this table are from the MAX 2002 file for Arkansas, released by CMS in 05/2006. This table was produced on 04/19/2007.

- a. Table ND.4 includes the beneficiaries represented by Cell K of Table 1. Benefit months are months during which beneficiaries had fee-for-service pharmacy benefits.
- b. The Medicaid reimbursement amounts presented in this table do not reflect federally required rebates from drug manufacturers to the state.
- c. Medicaid basis of eligibility is classified as: aged, disabled, adults, and children. The disabled group includes beneficiaries of any age who were determined to be eligible because of disability or blindness. The children's group includes children receiving foster care and adoptive services.
- d. Please refer to footnote f of Table 1 for methodology used to determine nursing facility residence.

Bene(s) = beneficiary (or beneficiaries); Bene Mo(s) = benefit month(s); CMS = Center for Medicare and Medicaid Services; MAX = Medicaid Analytic Extract; Rx = prescription(s) or pharmacy benefit; \$ = Medicaid reimbursement.

TABLE ND.5
 MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT PER BENEFIT MONTH, BY BRAND STATUS AND BENEFICIARY CHARACTERISTIC^{a, b, c}
 NONDUAL BENEFICIARIES, ARKANSAS, 2002

| Beneficiary Characteristics | All Rx | | Patented Brand-Name Drugs | | Off-Patent Brand-Name Drugs | | Generic Drugs | |
|----------------------------------------------|------------|-------------|---------------------------|-------------|-----------------------------|------------|---------------|------------|
| | No. of Rx | Rx \$ | No. of Rx | \$ per Rx | No. of Rx | Rx \$ | No. of Rx | Rx \$ |
| All | 0.6 | \$31 | 0.3 | \$53 | 0.0 | \$2 | 0.3 | \$5 |
| Age | | | | | | | | |
| 5 and younger | 0.6 | 21 | 0.2 | 37 | 0.0 | 2 | 0.3 | 4 |
| 6-14 | 0.5 | 26 | 0.2 | 55 | 0.0 | 3 | 0.2 | 4 |
| 15-20 | 0.4 | 25 | 0.2 | 56 | 0.0 | 2 | 0.2 | 4 |
| 21-44 | 0.4 | 28 | 0.2 | 62 | 0.0 | 2 | 0.2 | 5 |
| 45-64 | 2.4 | 139 | 1.0 | 59 | 0.2 | 8 | 1.2 | 26 |
| 65-74 | 2.1 | 107 | 0.9 | 50 | 0.1 | 7 | 1.1 | 22 |
| 75-84 | 2.1 | 99 | 0.9 | 47 | 0.2 | 6 | 1.0 | 20 |
| 85 and older | 1.3 | 59 | 0.5 | 44 | 0.1 | 4 | 0.7 | 13 |
| Unknown | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 |
| Basis of Eligibility^d | | | | | | | | |
| Aged | 2.1 | 98 | 0.8 | 47 | 0.2 | 7 | 1.1 | 20 |
| Disabled | 1.8 | 128 | 0.8 | 73 | 0.1 | 8 | 0.8 | 19 |
| Adults | 0.3 | 9 | 0.1 | 37 | 0.0 | 1 | 0.1 | 2 |
| Children | 0.5 | 18 | 0.2 | 39 | 0.0 | 2 | 0.2 | 3 |
| Unknown | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 |
| Gender | | | | | | | | |
| Female | 0.6 | 27 | 0.2 | 48 | 0.0 | 2 | 0.3 | 5 |
| Male | 0.6 | 38 | 0.3 | 59 | 0.1 | 3 | 0.3 | 6 |
| Unknown | 0.7 | 33 | 0.3 | 49 | 0.1 | 3 | 0.3 | 6 |
| Race | | | | | | | | |
| White | 0.6 | 34 | 0.3 | 53 | 0.1 | 3 | 0.3 | 6 |
| African American | 0.5 | 23 | 0.2 | 48 | 0.0 | 2 | 0.2 | 4 |
| Other/unknown | 0.7 | 44 | 0.3 | 63 | 0.1 | 3 | 0.3 | 7 |
| Use of Nursing Facilities^e | | | | | | | | |
| Entire year | 6.2 | 340 | 2.4 | 54 | 0.5 | 20 | 3.3 | 65 |
| Part year | 4.7 | 276 | 1.9 | 59 | 0.4 | 15 | 2.5 | 57 |
| None | 0.6 | 30 | 0.2 | 53 | 0.0 | 2 | 0.3 | 5 |
| Maintenance Assistance Status | | | | | | | | |
| Cash | 1.2 | 78 | 0.5 | 65 | 0.1 | 5 | 0.6 | 13 |
| Medically needy | 0.9 | 54 | 0.4 | 58 | 0.1 | 4 | 0.5 | 10 |
| Poverty related | 0.5 | 17 | 0.2 | 37 | 0.0 | 2 | 0.2 | 3 |
| Other/unknown | 0.3 | 15 | 0.1 | 49 | 0.0 | 2 | 0.1 | 2 |

Source: Data for this table are from the MAX 2002 file for Arkansas, released by CMS in 05/2006. This table was produced on 04/19/2007.

- a. Table ND.5 includes the beneficiaries represented by Cell K of Table 1. Benefit months are months during which beneficiaries had fee-for-service pharmacy benefits.
- b. The Medicaid reimbursement amounts presented in this table do not reflect federally required rebates from drug manufacturers to the state.
- c. Brand-name drugs, sometimes called "innovator single-source drugs," are drugs whose patents have not yet expired. Off-patent brand-name drugs, sometimes called "innovator multiple-source drugs," are brand-name drugs whose patents have expired. Generic drugs, sometimes called "non-innovator multiple-source drugs," are off-patent drugs manufactured and sold by companies other than the original patent holder. In Arkansas, 0.2 percent of drug claims have missing values for brand status. Thus, the sum of the three groups in this table may be smaller than all combined. For information about this classification method, see Wolters Kluwer Health, http://www.Medi-Span.com/products/product_mddb.asp (May 13 2003).
- d. Medicaid basis of eligibility is classified as: aged, disabled, adults, and children. The disabled group includes beneficiaries of any age who were determined to be eligible because of disability or blindness. The children's group includes children receiving foster care and adoptive services.
- e. Please refer to footnote f of Table 1 for methodology used to determine nursing facility residence.

CMS = Center for Medicare and Medicaid Services; MAX = Medicaid Analytic Extract; Rx = prescription(s) or pharmacy benefit; \$ = Medicaid reimbursement.

TABLE ND.6

MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT, BY BRAND STATUS AND THERAPEUTIC CATEGORY^{a, b, c, d}
 NONDUAL BENEFICIARIES, ARKANSAS, 2002

| Therapeutic Category | No. of Rx per Bene Mo among Users | | | | \$ per Bene Mo among Users | | | | Total No. of Rx | Total Rx \$ | No. | As % of All Benes | No. of Bene Mos | | | | |
|-------------------------------------------------|-----------------------------------|------------|------------|-------|----------------------------|---------|------------|------------|-----------------|-------------|-------|-------------------|-----------------|--------------|---------|--------|-----------|
| | Patented | | Off-Patent | | Patented | | Off-Patent | | | | | | | | | | |
| | Total | Brand-Name | Generic | Total | Brand-Name | Generic | Total | Brand-Name | | | | | | Generic | | | |
| Anti-infective Agents | 0.2 | 0.1 | 0.0 | 0.1 | \$10 | \$8 | \$1 | \$2 | \$41 | \$64 | \$66 | \$14 | 573,792 | \$23,534,279 | 223,696 | 40.8 % | 2,340,887 |
| Biologicals | 0.3 | 0.3 | 0.0 | 0.0 | 472 | 434 | 12 | 26 | 1466 | 1,425 | 1,080 | 4,228 | 3,469 | 5,087,016 | 1,188 | 0.2 | 10,784 |
| Antineoplastic Agents | 0.5 | 0.3 | 0.0 | 0.2 | 131 | 115 | 4 | 13 | 247 | 438 | 127 | 54 | 6,922 | 1,706,857 | 1,272 | 0.2 | 12,991 |
| Endocrine/Metabolic Drugs | 0.4 | 0.2 | 0.1 | 0.1 | 17 | 13 | 2 | 2 | 47 | 70 | 33 | 20 | 245,316 | 11,636,403 | 63,533 | 11.6 | 678,123 |
| Cardiovascular Agents | 0.9 | 0.3 | 0.1 | 0.5 | 31 | 20 | 2 | 9 | 35 | 61 | 39 | 17 | 262,024 | 9,128,457 | 27,870 | 5.1 | 291,606 |
| Respiratory Agents | 0.3 | 0.2 | 0.0 | 0.1 | 14 | 10 | 2 | 2 | 41 | 65 | 36 | 16 | 563,592 | 22,847,579 | 158,191 | 28.9 | 1,667,977 |
| Gastrointestinal Agents | 0.3 | 0.2 | 0.0 | 0.2 | 23 | 19 | 2 | 3 | 68 | 111 | 169 | 17 | 111,029 | 7,531,217 | 31,068 | 5.7 | 325,815 |
| Genitourinary Agents | 0.2 | 0.1 | 0.0 | 0.1 | 9 | 8 | 0 | 1 | 45 | 55 | 50 | 16 | 31,593 | 1,406,754 | 15,108 | 2.8 | 156,954 |
| CNS Drugs | 0.6 | 0.3 | 0.0 | 0.3 | 46 | 38 | 1 | 6 | 80 | 134 | 89 | 24 | 364,244 | 29,179,858 | 60,604 | 11.1 | 641,017 |
| Stimulants/Anti-obesity/Anorexia | 0.5 | 0.3 | 0.1 | 0.1 | 36 | 25 | 5 | 6 | 67 | 77 | 68 | 42 | 122,882 | 8,176,700 | 20,765 | 3.8 | 224,245 |
| Miscellaneous Psychological/Neurological Agents | 0.5 | 0.4 | 0.0 | 0.2 | 68 | 64 | 0 | 4 | 131 | 181 | 0 | 23 | 3,320 | 434,686 | 606 | 0.1 | 6,371 |
| Analgesics and Anesthetics | 0.3 | 0.0 | 0.0 | 0.2 | 9 | 5 | 1 | 3 | 35 | 131 | 61 | 15 | 268,573 | 9,355,262 | 94,717 | 17.3 | 993,389 |
| Neuromuscular Agents | 0.6 | 0.3 | 0.1 | 0.2 | 42 | 32 | 4 | 6 | 73 | 123 | 56 | 24 | 165,903 | 12,183,910 | 27,282 | 5.0 | 291,537 |
| Nutritional Products | 0.3 | 0.0 | 0.0 | 0.2 | 4 | 0 | 0 | 3 | 15 | 23 | 13 | 15 | 51,300 | 765,280 | 19,236 | 3.5 | 192,719 |
| Hematological Agents | 0.5 | 0.2 | 0.1 | 0.3 | 173 | 158 | 1 | 14 | 334 | 939 | 22 | 47 | 25,546 | 8,521,312 | 4,796 | 0.9 | 49,218 |
| Topical Products | 0.2 | 0.1 | 0.0 | 0.1 | 6 | 4 | 0 | 2 | 30 | 54 | 32 | 15 | 204,583 | 6,055,263 | 102,436 | 18.7 | 1,088,657 |
| Miscellaneous Products | 0.2 | 0.1 | 0.0 | 0.1 | 16 | 11 | 3 | 2 | 95 | 114 | 269 | 31 | 12,733 | 1,214,987 | 7,136 | 1.3 | 74,408 |
| Unknown Therapeutic Category | 0.1 | 0.0 | 0.0 | 0.0 | 3 | 0 | 0 | 0 | 22 | 0 | 0 | 0 | 4,559 | 101,015 | 2,894 | 0.5 | 31,961 |
| TOTAL NO. OF RX AND RX \$ | n.a. | n.a. | n.a. | n.a. | n.a. | n.a. | n.a. | n.a. | n.a. | n.a. | n.a. | n.a. | 3,021,380 | 158,866,835 | n.a. | n.a. | n.a. |

Source: Data for this table are from the MAX 2002 file for Arkansas, released by CMS in 05/2006. This table was produced on 04/19/2007.

a. Table ND.6 includes the beneficiaries represented by Cell K of Table 1. A user is a beneficiary who had at least one prescription filled in a given therapeutic category during 2002. A beneficiary who used drugs from two or more categories was counted as a user for each category. Therefore, the sum of users across categories may exceed the total number of individual users. Benefit months are months during which beneficiaries had fee-for-service pharmacy benefits.

b. Medicaid reimbursement amounts presented in this table do not reflect federally required rebates from drug manufacturers to the state.

c. For information about these therapeutic categories, see Wolters Kluwer Health, http://www.Medi-Span.com/products/product_mddb.asp (May 13 2003).

d. Brand-name drugs, sometimes called "innovator single-source drugs," are drugs whose patents have not yet expired. Off-patent brand-name drugs, sometimes called "innovator multiple-source drugs," are brand-name drugs whose patents have expired. Generic drugs, sometimes called "non-innovator multiple-source drugs," are off-patent drugs manufactured and sold by companies other than the original patent holder. In Arkansas, 0.2 percent of drug claims have missing values for brand status. Thus, the sum of the three groups in this table may be smaller than all prescriptions combined. For information about this classification method, see Wolters Kluwer Health, http://www.Medi-Span.com/products/product_mddb.asp (May 13 2003).

Bene(s) = beneficiary (or beneficiaries); Bene Mo(s) = benefit month(s); CMS = Center for Medicare and Medicaid Services; CNS = Central Nervous System; MAX = Medicaid Analytic Extract; n.a. = not applicable; Rx = prescription(s) or pharmacy benefit; \$ = Medicaid reimbursement.

TABLE ND.7
 MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT, BY TOP 10 DRUG GROUP^{a, b, c}
 NONDUAL BENEFICIARIES, ARKANSAS, 2002

| Top 10 Drug Groups | Users | | | | Among Users | | |
|-------------------------------------|----------------------|-----------------------|-----------------|-----------------------|-------------|-------------------|--|
| | Total Medicaid Rx \$ | No. As % of All Benes | No. of Bene Mos | No. of Rx per Bene Mo | \$ per Rx | Rx \$ per Bene Mo | |
| ANTIPSYCHOTICS | \$16,221,737 | 16,177 | 177,129 | 0.5 | \$187 | \$92 | |
| ANTIASTHMATIC | 10,701,591 | 75,080 | 805,812 | 0.2 | 54 | 13 | |
| ANTIDEPRESSANTS | 10,600,678 | 41,726 | 442,377 | 0.4 | 61 | 24 | |
| ANTICONVULSANT | 10,422,760 | 18,035 | 196,016 | 0.6 | 90 | 53 | |
| STIMULANTS/ANTI-OBESITY/ANOREXIANTS | 8,176,700 | 23,729 | 258,757 | 0.5 | 67 | 32 | |
| MISC. HEMATOLOGICAL | 6,861,097 | 1,606 | 16,846 | 0.5 | 815 | 407 | |
| ANTIHISTAMINES | 6,267,534 | 84,453 | 920,987 | 0.2 | 41 | 7 | |
| ULCER DRUGS | 5,745,931 | 28,347 | 301,265 | 0.3 | 71 | 19 | |
| PENICILLINS | 5,386,462 | 152,594 | 1,633,455 | 0.1 | 25 | 3 | |
| ANALGESICS - Narcotic | 5,215,202 | 91,206 | 957,800 | 0.2 | 30 | 5 | |
| Total | 85,599,692 | 532,953 | 5,710,444 | n.a. | n.a. | n.a. | |

Source: Data for this table are from the MAX 2002 file for Arkansas, released by CMS in 05/2006. This table was produced on 04/19/2007.

a. Table ND.7 includes the beneficiaries represented by Cell K of Table 1. A user is a beneficiary who had at least one prescription filled in a given drug group during 2002. A beneficiary who used drugs from two or more groups was counted as a user for each group. Therefore, the sum of users across drug groups may exceed the total number of individual users. Benefit months are months during which beneficiaries had fee-for-service pharmacy benefits.

b. Medicaid reimbursement amounts presented in this table do not reflect federally required rebates from drug manufacturers to the state.

c. The top 10 drug groups were determined based on total Medicaid reimbursement in the state for 2002. For information about these drug groups, see Wolters Kluwer Health, http://www.Medi-Span.com/products/product_mddb.asp (May 13 2003).

Bene(s) = beneficiary (or beneficiaries); Bene Mo(s) = benefit month(s); CMS = Center for Medicare and Medicaid Services; MAX = Medicaid Analytic Extract; Rx = prescription(s) or pharmacy benefit; \$ = Medicaid reimbursement.

TABLE ND.7A
 MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT PER BENEFIT MONTH FOR TOP 10 DRUG GROUPS COMBINED
 AND FIRST AND SECOND GROUPS SEPARATELY, BY SEX, BOE, AND AGE^{a,b,c}
 NONDUAL BENEFICIARIES, ARKANSAS, 2002

| Beneficiary Characteristics | All Top 10 Drug Groups | | | | | ANTI-PSYCHOTICS | | | | | ANTI-ASTHMATIC | | | | | | |
|-----------------------------|------------------------|---------------------|---------------|-------------------------|-----------------------------|-----------------|-------------|---------------|-------------------------|-----------------------------|----------------|-------------|--------------|-------------------------|-----------------------------|----------------|------------|
| | No. of Rx | Rx \$ | No. of Users | Users as % of All Benes | No. of Bene Mos among Users | Mean No. of Rx | Mean Rx \$ | No. of Users | Users as % of All Benes | No. of Bene Mos among Users | Mean No. of Rx | Mean Rx \$ | No. of Users | Users as % of All Benes | No. of Bene Mos among Users | Mean No. of Rx | Mean Rx \$ |
| All | 1,335,172 | \$85,599,692 | 16,177 | 3.0 % | 177,129 | 0.5 | \$92 | 75,080 | 13.7 % | 805,812 | 0.2 | \$13 | | | | | |
| Female | 719,188 | 41,677,101 | 8,063 | 2.4 | 88,283 | 0.5 | 87 | 35,819 | 10.6 | 384,632 | 0.2 | 13 | | | | | |
| Disabled | 310,641 | 24,768,171 | 5,834 | 15.9 | 65,450 | 0.5 | 99 | 8,945 | 24.4 | 99,890 | 0.4 | 21 | | | | | |
| 5 and younger | 11,660 | 580,261 | 19 | 0.8 | 221 | 0.5 | 69 | 1,014 | 44.7 | 11,455 | 0.3 | 14 | | | | | |
| 6-14 | 31,997 | 2,290,682 | 443 | 11.1 | 5,012 | 0.5 | 76 | 1,098 | 27.5 | 12,632 | 0.3 | 22 | | | | | |
| 15-20 | 21,792 | 1,875,250 | 431 | 14.4 | 4,896 | 0.4 | 75 | 549 | 18.3 | 6,259 | 0.3 | 18 | | | | | |
| 21-44 | 98,880 | 8,488,020 | 2,539 | 21.4 | 28,345 | 0.5 | 96 | 2,200 | 18.5 | 24,587 | 0.3 | 18 | | | | | |
| 45-64 | 141,131 | 11,160,303 | 2,323 | 16.2 | 26,051 | 0.6 | 112 | 3,957 | 27.5 | 43,504 | 0.4 | 24 | | | | | |
| 65-74 | 4,413 | 317,010 | 68 | 9.0 | 802 | 0.7 | 121 | 111 | 14.8 | 1,261 | 0.5 | 25 | | | | | |
| 75-84 | 690 | 49,837 | 11 | 4.5 | 123 | 0.9 | 125 | 12 | 4.9 | 144 | 0.4 | 19 | | | | | |
| 85 and older | 78 | 6,808 | 0 | 0.0 | 0 | 0.0 | 0 | 4 | 3.8 | 48 | 0.4 | 45 | | | | | |
| Other Eligibles | 408,547 | 16,908,930 | 2,229 | 0.7 | 22,833 | 0.3 | 50 | 26,874 | 8.9 | 284,742 | 0.2 | 11 | | | | | |
| 5 and younger | 103,669 | 3,056,249 | 55 | 0.1 | 618 | 0.3 | 40 | 11,227 | 17.5 | 118,520 | 0.2 | 8 | | | | | |
| 6-14 | 132,449 | 6,235,989 | 674 | 0.9 | 7,324 | 0.4 | 50 | 9,025 | 12.3 | 99,578 | 0.2 | 13 | | | | | |
| 15-20 | 69,450 | 2,941,468 | 518 | 1.0 | 5,397 | 0.3 | 41 | 3,362 | 6.3 | 35,467 | 0.2 | 11 | | | | | |
| 21-44 | 83,848 | 3,431,825 | 709 | 0.7 | 6,767 | 0.3 | 44 | 2,773 | 2.6 | 26,383 | 0.2 | 9 | | | | | |
| 45-64 | 6,089 | 347,320 | 34 | 1.1 | 293 | 0.4 | 61 | 207 | 6.9 | 1,905 | 0.3 | 17 | | | | | |
| 65-74 | 3,361 | 230,493 | 60 | 14.2 | 611 | 0.7 | 89 | 87 | 20.6 | 951 | 0.5 | 28 | | | | | |
| 75-84 | 5,345 | 376,968 | 88 | 12.3 | 886 | 0.7 | 97 | 119 | 16.6 | 1,184 | 0.5 | 31 | | | | | |
| 85 and older | 4,336 | 288,618 | 91 | 8.9 | 937 | 0.6 | 84 | 74 | 7.3 | 754 | 0.4 | 21 | | | | | |
| Male | 614,562 | 43,851,160 | 8,104 | 3.9 | 88,732 | 0.5 | 97 | 39,156 | 18.7 | 420,174 | 0.2 | 13 | | | | | |
| Disabled | 242,403 | 25,688,456 | 5,608 | 16.0 | 62,730 | 0.6 | 112 | 7,448 | 21.3 | 82,979 | 0.3 | 20 | | | | | |
| 5 and younger | 19,097 | 1,189,174 | 111 | 3.2 | 1,218 | 0.4 | 58 | 1,852 | 54.2 | 20,974 | 0.3 | 16 | | | | | |
| 6-14 | 72,203 | 7,661,784 | 1,420 | 18.4 | 16,166 | 0.5 | 82 | 2,329 | 30.1 | 26,647 | 0.3 | 20 | | | | | |
| 15-20 | 33,204 | 4,242,099 | 893 | 19.1 | 10,137 | 0.5 | 99 | 811 | 17.4 | 9,266 | 0.3 | 19 | | | | | |
| 21-44 | 57,462 | 7,683,070 | 2,008 | 20.5 | 22,218 | 0.6 | 134 | 794 | 8.1 | 8,775 | 0.3 | 18 | | | | | |
| 45-64 | 58,184 | 4,739,782 | 1,129 | 12.8 | 12,460 | 0.6 | 125 | 1,608 | 18.3 | 16,715 | 0.5 | 28 | | | | | |
| 65-74 | 1,976 | 152,654 | 43 | 11.1 | 487 | 0.8 | 133 | 45 | 11.6 | 494 | 0.5 | 40 | | | | | |
| 75-84 | 277 | 19,893 | 4 | 3.7 | 44 | 1.0 | 142 | 9 | 8.3 | 108 | 0.6 | 23 | | | | | |
| 85 and older | 0 | 0 | 0 | 0.0 | 0 | 0.0 | 0 | 0 | 0.0 | 0 | 0.0 | 0 | | | | | |
| Other Eligibles | 372,159 | 18,162,704 | 2,496 | 1.4 | 26,002 | 0.4 | 61 | 31,708 | 18.2 | 337,195 | 0.2 | 12 | | | | | |
| 5 and younger | 128,267 | 4,332,424 | 124 | 0.2 | 1,257 | 0.3 | 51 | 16,195 | 23.8 | 169,086 | 0.2 | 9 | | | | | |
| 6-14 | 185,500 | 10,262,733 | 1,491 | 2.0 | 15,856 | 0.4 | 58 | 12,507 | 16.6 | 136,712 | 0.2 | 14 | | | | | |
| 15-20 | 45,025 | 2,690,950 | 679 | 2.5 | 6,920 | 0.4 | 63 | 2,642 | 9.9 | 27,996 | 0.2 | 14 | | | | | |
| 21-44 | 5,133 | 323,583 | 50 | 1.9 | 420 | 0.4 | 89 | 126 | 4.9 | 1,056 | 0.3 | 16 | | | | | |
| 45-64 | 1,724 | 120,858 | 8 | 1.5 | 51 | 0.2 | 20 | 58 | 10.6 | 508 | 0.3 | 17 | | | | | |
| 65-74 | 2,668 | 196,035 | 69 | 20.6 | 722 | 0.6 | 95 | 53 | 15.8 | 559 | 0.4 | 22 | | | | | |
| 75-84 | 2,416 | 148,440 | 38 | 9.9 | 419 | 0.6 | 78 | 104 | 27.2 | 1,037 | 0.5 | 26 | | | | | |
| 85 and older | 1,426 | 87,681 | 37 | 9.9 | 357 | 0.6 | 76 | 23 | 6.1 | 241 | 0.4 | 17 | | | | | |
| Unknown | 1,422 | 71,431 | 10 | 1.4 | 114 | 0.3 | 75 | 105 | 15.2 | 1,006 | 0.2 | 10 | | | | | |

Table ND7A
 Nondual Beneficiaries

Source: Data for this table are from the MAX 2002 file for Arkansas, released by CMS in 05/2006. This table was produced on 04/19/2007.

a. Table ND.7A includes the beneficiaries represented by Cell K of Table 1. A user is a beneficiary who had at least one prescription filled in a given drug group during 2002. A beneficiary who used drugs from two or more drug groups was counted as a user for each group. Therefore, the sum of users across drug groups may exceed the total number of individual users. Benefit months are months during which beneficiaries had fee-for-service pharmacy benefits.

b. Medicaid reimbursement amounts presented in this table do not reflect federally required rebates from drug manufacturers to the state.

c. The top 10 drug groups were determined based on total Medicaid reimbursement in the state for 2002. For information about these drug groups, see Wolters Kluwer Health, http://www.Medi-Span.com/products/product_mddb.asp (May 13 2003).

Bene(s) = beneficiary (or beneficiaries); Bene Mo(s) = benefit month(s); BOE = basis of eligibility; CMS = Center for Medicare and Medicaid Services; MAX = Medicaid Analytic Extract; Rx = prescription(s) or pharmacy benefit; \$ = Medicaid reimbursement.

TABLE ND.7B
 MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT PER BENEFIT MONTH FOR THIRD TO FIFTH TOP DRUG GROUPS SEPARATELY,
 BY SEX, BOE, AND AGE^{a, b, c}
 NONDUAL BENEFICIARIES, ARKANSAS, 2002

| Beneficiary Characteristics | ANTIDEPRESSANTS | | | | | ANTICONVULSANT | | | | | STIMULANTS/ANTI-OBESITY/ANOREXIANTS | | | | |
|-----------------------------|-----------------|-------------------------|-----------------------------|------------|----------------|----------------|-------------------------|-----------------------------|------------|----------------|-------------------------------------|-------------------------|-----------------------------|------------|----------------|
| | No. of Users | Users as % of All Benes | No. of Bene Mos among Users | Mean Rx | Mean No. of Rx | No. of Users | Users as % of All Benes | No. of Bene Mos among Users | Mean Rx | Mean No. of Rx | No. of Users | Users as % of All Benes | No. of Bene Mos among Users | Mean Rx | Mean No. of Rx |
| All | 41,726 | 7.6 % | 442,377 | 0.4 | 0.4 | 18,035 | 3.3 % | 196,016 | 0.6 | 0.6 | 23,729 | 4.3 % | 258,757 | 0.5 | \$32 |
| Female | 27,782 | 8.2 | 293,286 | 0.4 | 0.4 | 9,976 | 3.0 | 108,180 | 0.6 | 0.6 | 6,440 | 1.9 | 71,035 | 0.5 | 31 |
| Disabled | 13,074 | 35.7 | 144,886 | 0.5 | 0.5 | 6,957 | 19.0 | 77,778 | 0.6 | 0.6 | 1,376 | 3.8 | 15,746 | 0.5 | 36 |
| 5 and younger | 30 | 1.3 | 339 | 0.4 | 0.4 | 234 | 10.3 | 2,634 | 0.7 | 0.7 | 56 | 2.5 | 632 | 0.3 | 20 |
| 6-14 | 706 | 17.7 | 8,050 | 0.5 | 0.5 | 791 | 19.8 | 9,074 | 0.8 | 0.8 | 911 | 22.8 | 10,512 | 0.5 | 36 |
| 15-20 | 947 | 31.6 | 10,760 | 0.4 | 0.4 | 582 | 19.4 | 6,674 | 0.7 | 0.7 | 227 | 7.6 | 2,595 | 0.5 | 35 |
| 21-44 | 5,366 | 45.2 | 59,644 | 0.4 | 0.4 | 2,747 | 23.1 | 30,601 | 0.6 | 0.6 | 106 | 0.9 | 1,162 | 0.5 | 44 |
| 45-64 | 5,887 | 40.9 | 64,489 | 0.5 | 0.5 | 2,527 | 17.6 | 27,928 | 0.6 | 0.6 | 76 | 0.5 | 845 | 0.5 | 44 |
| 65-74 | 126 | 16.8 | 1,465 | 0.6 | 0.6 | 60 | 8.0 | 686 | 0.7 | 0.7 | 0 | 0.0 | 0 | 0.0 | 0 |
| 75-84 | 11 | 4.5 | 127 | 0.6 | 0.6 | 15 | 6.1 | 169 | 0.8 | 0.8 | 0 | 0.0 | 0 | 0.0 | 0 |
| 85 and older | 1 | 1.0 | 12 | 0.9 | 0.9 | 1 | 1.0 | 12 | 0.8 | 0.8 | 0 | 0.0 | 0 | 0.0 | 0 |
| Other Eligibles | 14,708 | 4.9 | 148,400 | 0.3 | 0.3 | 3,019 | 1.0 | 30,402 | 0.4 | 0.4 | 5,064 | 1.7 | 55,289 | 0.4 | 29 |
| 5 and younger | 135 | 0.2 | 1,493 | 0.2 | 0.2 | 197 | 0.3 | 2,115 | 0.4 | 0.4 | 38 | 0.5 | 3,578 | 0.3 | 16 |
| 6-14 | 2,990 | 4.1 | 32,983 | 0.3 | 0.3 | 694 | 0.9 | 7,553 | 0.5 | 0.5 | 4,037 | 5.5 | 44,347 | 0.5 | 30 |
| 15-20 | 4,242 | 8.0 | 44,414 | 0.3 | 0.3 | 618 | 1.2 | 6,442 | 0.4 | 0.4 | 37 | 1.1 | 5,947 | 0.4 | 32 |
| 21-44 | 6,448 | 6.1 | 60,794 | 0.3 | 0.3 | 1,229 | 1.2 | 11,508 | 0.3 | 0.3 | 131 | 0.1 | 1,315 | 0.4 | 36 |
| 45-64 | 492 | 16.5 | 4,563 | 0.4 | 0.4 | 118 | 3.9 | 1,105 | 0.4 | 0.4 | 7 | 0.2 | 81 | 0.3 | 39 |
| 65-74 | 106 | 25.1 | 1,101 | 0.6 | 0.6 | 55 | 13.0 | 556 | 0.7 | 0.7 | 0 | 0.0 | 0 | 0.0 | 0 |
| 75-84 | 157 | 21.9 | 1,627 | 0.7 | 0.7 | 64 | 8.9 | 668 | 0.7 | 0.7 | 2 | 0.3 | 21 | 0.7 | 62 |
| 85 and older | 138 | 13.5 | 1,425 | 0.8 | 0.8 | 44 | 4.3 | 455 | 0.8 | 0.8 | 0 | 0.0 | 0 | 0.0 | 0 |
| Male | 13,894 | 6.6 | 148,558 | 0.4 | 0.4 | 8,048 | 3.8 | 87,706 | 0.6 | 0.6 | 17,264 | 8.3 | 187,445 | 0.5 | 32 |
| Disabled | 6,714 | 19.2 | 73,582 | 0.5 | 0.5 | 5,769 | 16.5 | 64,173 | 0.7 | 0.7 | 4,270 | 12.2 | 48,540 | 0.5 | 36 |
| 5 and younger | 97 | 2.8 | 1,102 | 0.4 | 0.4 | 313 | 9.2 | 3,487 | 0.7 | 0.7 | 265 | 7.8 | 2,970 | 0.4 | 20 |
| 6-14 | 1,730 | 22.4 | 19,709 | 0.5 | 0.5 | 1,560 | 20.2 | 17,739 | 0.7 | 0.7 | 3,117 | 40.3 | 35,403 | 0.6 | 38 |
| 15-20 | 1,155 | 24.7 | 13,095 | 0.5 | 0.5 | 882 | 18.9 | 10,046 | 0.7 | 0.7 | 762 | 16.3 | 8,756 | 0.5 | 35 |
| 21-44 | 1,975 | 20.1 | 21,203 | 0.5 | 0.5 | 1,845 | 18.8 | 20,311 | 0.7 | 0.7 | 97 | 1.0 | 1,110 | 0.6 | 45 |
| 45-64 | 1,715 | 19.5 | 17,988 | 0.5 | 0.5 | 1,141 | 13.0 | 12,299 | 0.7 | 0.7 | 29 | 0.3 | 301 | 0.6 | 54 |
| 65-74 | 36 | 9.3 | 413 | 0.6 | 0.6 | 26 | 6.7 | 272 | 0.8 | 0.8 | 0 | 0.0 | 0 | 0.0 | 0 |
| 75-84 | 6 | 5.6 | 72 | 0.6 | 0.6 | 2 | 1.9 | 19 | 0.7 | 0.7 | 0 | 0.0 | 0 | 0.0 | 0 |
| 85 and older | 0 | 0.0 | 0 | 0.0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 |
| Other Eligibles | 7,180 | 4.1 | 74,976 | 0.4 | 0.4 | 2,279 | 1.3 | 23,533 | 0.5 | 0.5 | 12,994 | 7.5 | 138,905 | 0.5 | 31 |
| 5 and younger | 215 | 0.3 | 2,333 | 0.3 | 0.3 | 283 | 0.4 | 2,944 | 0.4 | 0.4 | 731 | 1.1 | 7,889 | 0.3 | 17 |
| 6-14 | 4,124 | 5.5 | 44,547 | 0.4 | 0.4 | 1,160 | 1.5 | 12,386 | 0.4 | 0.4 | 10,901 | 14.5 | 116,664 | 0.5 | 31 |
| 15-20 | 2,190 | 8.2 | 22,402 | 0.3 | 0.3 | 549 | 2.1 | 5,596 | 0.5 | 0.5 | 1,347 | 5.0 | 14,216 | 0.4 | 31 |
| 21-44 | 362 | 14.0 | 2,967 | 0.3 | 0.3 | 144 | 5.6 | 1,222 | 0.4 | 0.4 | 8 | 0.3 | 77 | 0.4 | 53 |
| 45-64 | 114 | 20.9 | 964 | 0.4 | 0.4 | 49 | 9.0 | 414 | 0.4 | 0.4 | 4 | 0.7 | 30 | 0.3 | 27 |
| 65-74 | 70 | 20.9 | 709 | 0.6 | 0.6 | 42 | 12.5 | 459 | 0.9 | 0.9 | 1 | 0.3 | 12 | 0.1 | 13 |
| 75-84 | 55 | 14.4 | 543 | 0.7 | 0.7 | 36 | 9.4 | 374 | 0.7 | 0.7 | 0 | 0.0 | 0 | 0.0 | 0 |
| 85 and older | 50 | 13.3 | 511 | 0.7 | 0.7 | 16 | 4.3 | 138 | 0.7 | 0.7 | 2 | 0.5 | 17 | 0.5 | 7 |
| Unknown | 50 | 7.2 | 533 | 0.4 | 0.4 | 11 | 1.6 | 130 | 0.4 | 0.4 | 25 | 3.6 | 277 | 0.4 | 30 |

Table ND7B
 Nondual Beneficiaries

Source: Data for this table are from the MAX 2002 file for Arkansas, released by CMS in 05/2006. This table was produced on 04/19/2007.

- a. Table ND.7B includes the beneficiaries represented by Cell K of Table 1. A user is a beneficiary who had at least one prescription filled in a given drug group during 2002. A beneficiary who used drugs from two or more drug groups was counted as a user for each group. Therefore, the sum of users across drug groups may exceed the total number of individual users. Benefit months are months during which beneficiaries had fee-for-service pharmacy benefits.
 - b. Medicaid reimbursement amounts presented in this table do not reflect federally required rebates from drug manufacturers to the state.
 - c. The top 10 drug groups were determined based on total Medicaid reimbursement in the state for 2002. For information about these drug groups, see Wolters Kluwer Health, http://www.Medi-Span.com/products/product_mddb.asp (May 13 2003).
- Bene(s) = beneficiary (or beneficiaries); Bene Mo(s) = benefit month(s); BOE = basis of eligibility; CMS = Center for Medicare and Medicaid Services; MAX = Medicaid Analytic Extract; Rx = prescription(s) or pharmacy benefit; \$ = Medicaid reimbursement.

TABLE ND.7C
 MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT PER BENEFIT MONTH FOR SIXTH TO EIGHTH TOP DRUG GROUPS SEPARATELY,
 BY SEX, BOE, AND AGE^{a, b, c}
 NONDUAL BENEFICIARIES, ARKANSAS, 2002

| Beneficiary Characteristics | MISC. HEMATOLOGICAL | | | | | ANTIHISTAMINES | | | | | ULCER DRUGS | | | | |
|-----------------------------|---------------------|-------------------------|-----------------------------|----------------|--------------|----------------|-------------------------|-----------------------------|----------------|------------|---------------|-------------------------|-----------------------------|----------------|-------------|
| | No. of Users | Users as % of All Benes | No. of Bene Mos among Users | Mean No. of Rx | Mean Rx \$ | No. of Users | Users as % of All Benes | No. of Bene Mos among Users | Mean No. of Rx | Mean Rx \$ | No. of Users | Users as % of All Benes | No. of Bene Mos among Users | Mean No. of Rx | Mean Rx \$ |
| All | 1,606 | 0.3 % | 16,846 | 0.5 | \$407 | 84,453 | 15.4 % | 920,987 | 0.2 | \$7 | 28,347 | 5.2 % | 301,265 | 0.3 | \$19 |
| Female | 979 | 0.3 | 10,449 | 0.5 | 72 | 45,599 | 13.5 | 496,148 | 0.2 | 6 | 18,454 | 5.5 | 197,565 | 0.3 | 20 |
| Disabled | 775 | 2.1 | 8,480 | 0.5 | 73 | 5,933 | 16.2 | 67,866 | 0.2 | 9 | 8,673 | 23.7 | 97,858 | 0.3 | 28 |
| 5 and younger | 1 | 0.0 | 12 | 1.3 | 12 | 813 | 35.9 | 9,369 | 0.2 | 6 | 336 | 14.8 | 3,544 | 0.4 | 22 |
| 6-14 | 0 | 0.0 | 0 | 0.0 | 0 | 1,256 | 31.4 | 14,652 | 0.2 | 11 | 369 | 9.2 | 4,190 | 0.4 | 27 |
| 15-20 | 2 | 0.1 | 24 | 0.3 | 9,623 | 793 | 26.4 | 9,163 | 0.2 | 10 | 410 | 13.7 | 4,735 | 0.3 | 22 |
| 21-44 | 83 | 0.7 | 862 | 0.4 | 63 | 1,552 | 13.1 | 17,698 | 0.2 | 6 | 2,566 | 21.6 | 29,270 | 0.3 | 24 |
| 45-64 | 646 | 4.5 | 7,074 | 0.5 | 45 | 1,475 | 10.3 | 16,465 | 0.2 | 9 | 4,802 | 33.4 | 53,927 | 0.4 | 32 |
| 65-74 | 32 | 4.3 | 376 | 0.4 | 39 | 39 | 5.2 | 459 | 0.3 | 7 | 167 | 22.2 | 1,922 | 0.4 | 31 |
| 75-84 | 10 | 4.1 | 120 | 0.4 | 34 | 4 | 1.6 | 48 | 0.6 | 32 | 18 | 7.4 | 216 | 0.4 | 37 |
| 85 and older | 1 | 1.0 | 12 | 0.7 | 74 | 1 | 1.0 | 12 | 0.2 | 4 | 5 | 4.8 | 54 | 0.4 | 18 |
| Other Eligibles | 204 | 0.1 | 1,969 | 0.5 | 65 | 39,666 | 13.2 | 428,282 | 0.2 | 6 | 9,781 | 3.2 | 99,707 | 0.2 | 11 |
| 5 and younger | 1 | 0.0 | 10 | 0.2 | 216 | 14,676 | 22.8 | 158,356 | 0.1 | 4 | 2,147 | 3.3 | 19,616 | 0.2 | 6 |
| 6-14 | 1 | 0.0 | 12 | 0.1 | 371 | 14,799 | 20.1 | 164,734 | 0.2 | 8 | 2,072 | 2.8 | 23,242 | 0.2 | 8 |
| 15-20 | 3 | 0.0 | 34 | 0.2 | 837 | 6,031 | 11.4 | 64,468 | 0.2 | 7 | 1,983 | 3.7 | 21,314 | 0.1 | 8 |
| 21-44 | 40 | 0.0 | 357 | 0.2 | 20 | 3,901 | 3.7 | 38,136 | 0.2 | 4 | 2,836 | 2.7 | 27,982 | 0.2 | 14 |
| 45-64 | 23 | 0.8 | 195 | 0.4 | 34 | 101 | 3.4 | 949 | 0.2 | 6 | 268 | 9.0 | 2,560 | 0.3 | 25 |
| 65-74 | 20 | 4.7 | 225 | 0.5 | 49 | 33 | 7.8 | 369 | 0.2 | 9 | 114 | 27.0 | 1,232 | 0.4 | 28 |
| 75-84 | 71 | 9.9 | 688 | 0.7 | 65 | 56 | 7.8 | 601 | 0.3 | 11 | 200 | 27.9 | 2,099 | 0.5 | 35 |
| 85 and older | 45 | 4.4 | 448 | 0.6 | 51 | 69 | 6.8 | 669 | 0.3 | 10 | 161 | 15.8 | 1,662 | 0.6 | 36 |
| Male | 614 | 0.3 | 6,250 | 0.5 | 977 | 38,768 | 18.5 | 423,912 | 0.2 | 7 | 9,856 | 4.7 | 103,306 | 0.3 | 18 |
| Disabled | 472 | 1.3 | 4,880 | 0.5 | 1,149 | 5,232 | 15.0 | 59,726 | 0.2 | 10 | 4,390 | 12.6 | 48,444 | 0.4 | 27 |
| 5 and younger | 9 | 0.3 | 104 | 0.5 | 2,282 | 1,177 | 34.4 | 13,573 | 0.2 | 6 | 404 | 11.8 | 4,311 | 0.4 | 17 |
| 6-14 | 22 | 0.3 | 256 | 0.7 | 9,073 | 2,249 | 29.1 | 26,009 | 0.2 | 12 | 534 | 6.9 | 6,108 | 0.4 | 26 |
| 15-20 | 10 | 0.2 | 118 | 1.0 | 11,441 | 822 | 17.6 | 9,452 | 0.2 | 12 | 377 | 8.1 | 4,330 | 0.3 | 22 |
| 21-44 | 56 | 0.6 | 604 | 0.6 | 2,521 | 558 | 5.7 | 6,197 | 0.2 | 8 | 1,227 | 12.5 | 13,752 | 0.3 | 27 |
| 45-64 | 361 | 4.1 | 3,632 | 0.5 | 47 | 406 | 4.6 | 4,264 | 0.3 | 9 | 1,760 | 20.0 | 18,944 | 0.4 | 32 |
| 65-74 | 12 | 3.1 | 142 | 0.5 | 42 | 17 | 4.4 | 199 | 0.3 | 9 | 75 | 19.3 | 856 | 0.5 | 28 |
| 75-84 | 2 | 1.9 | 24 | 0.8 | 46 | 3 | 2.8 | 32 | 0.2 | 9 | 13 | 12.0 | 143 | 0.5 | 47 |
| 85 and older | 0 | 0.0 | 0 | 0.0 | 0 | 0 | 0.0 | 0 | 0.0 | 0 | 0 | 0.0 | 0 | 0.0 | 0 |
| Other Eligibles | 142 | 0.1 | 1,370 | 0.5 | 364 | 33,536 | 19.3 | 364,186 | 0.2 | 7 | 5,466 | 3.1 | 54,862 | 0.2 | 10 |
| 5 and younger | 6 | 0.0 | 66 | 0.5 | 2,350 | 16,128 | 23.7 | 173,028 | 0.1 | 4 | 2,442 | 3.6 | 22,247 | 0.2 | 8 |
| 6-14 | 8 | 0.0 | 90 | 0.4 | 1,521 | 14,383 | 19.1 | 158,808 | 0.2 | 9 | 1,682 | 2.2 | 18,853 | 0.2 | 8 |
| 15-20 | 4 | 0.0 | 48 | 0.3 | 3,063 | 2,879 | 10.8 | 30,934 | 0.2 | 9 | 850 | 3.2 | 9,004 | 0.2 | 11 |
| 21-44 | 18 | 0.7 | 122 | 0.5 | 46 | 67 | 2.6 | 590 | 0.2 | 6 | 174 | 6.8 | 1,467 | 0.3 | 23 |
| 45-64 | 18 | 3.3 | 143 | 0.4 | 42 | 15 | 2.8 | 139 | 0.3 | 8 | 76 | 13.9 | 742 | 0.3 | 32 |
| 65-74 | 37 | 11.0 | 394 | 0.6 | 58 | 21 | 6.3 | 337 | 0.2 | 5 | 93 | 27.8 | 1,011 | 0.4 | 27 |
| 75-84 | 29 | 7.6 | 282 | 0.6 | 49 | 32 | 8.4 | 342 | 0.3 | 14 | 90 | 23.6 | 931 | 0.5 | 22 |
| 85 and older | 22 | 5.9 | 225 | 0.6 | 49 | 11 | 2.9 | 108 | 0.3 | 7 | 59 | 15.7 | 607 | 0.5 | 27 |
| Unknown | 13 | 1.9 | 147 | 0.4 | 40 | 86 | 12.4 | 927 | 0.2 | 7 | 37 | 5.3 | 394 | 0.3 | 15 |

Table ND7C
 Nondual Beneficiaries

Source: Data for this table are from the MAX 2002 file for Arkansas, released by CMS in 05/2006. This table was produced on 04/19/2007.

- a. Table ND.7C includes the beneficiaries represented by Cell K of Table 1. A user is a beneficiary who had at least one prescription filled in a given drug group during 2002. A beneficiary who used drugs from two or more drug groups was counted as a user for each group. Therefore, the sum of users across drug groups may exceed the total number of individual users. Benefit months are months during which beneficiaries had fee-for-service pharmacy benefits.
 - b. Medicaid reimbursement amounts presented in this table do not reflect federally required rebates from drug manufacturers to the state.
 - c. The top 10 drug groups were determined based on total Medicaid reimbursement in the state for 2002. For information about these drug groups, see Wolters Kluwer Health, http://www.Medi-Span.com/products/product_mddb.asp (May 13 2003).
- Bene(s) = beneficiary (or beneficiaries); Bene Mo(s) = benefit month(s); BOE = basis of eligibility; CMS = Center for Medicare and Medicaid Services; MAX = Medicaid Analytic Extract; Rx = prescription(s) or pharmacy benefit; \$ = Medicaid reimbursement.

TABLE ND.7D
 MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT PER BENEFIT MONTH FOR NINTH AND TENTH TOP DRUG GROUPS
 SEPARATELY, BY SEX, BOE, AND AGE^{a, b, c}
 NONDUAL BENEFICIARIES, ARKANSAS, 2002

| Beneficiary Characteristics | PENICILLINS | | | | | ANALGESICS - Narcotic | | | | | | |
|-----------------------------|----------------|-------------------------|-----------------------------|----------------|------------|-----------------------|-------------------------|-----------------------------|----------------|------------|----------------|------------------|
| | No. of Users | Users as % of All Benes | No. of Bene Mos among Users | Mean No. of Rx | Mean Rx \$ | No. of Users | Users as % of All Benes | No. of Bene Mos among Users | Mean No. of Rx | Mean Rx \$ | | |
| | | | | | | | | | | | | |
| All | 152,594 | 27.9 % | 1,633,455 | 0.1 | \$3 | 91,206 | 16.6 % | 957,800 | 0.2 | \$5 | 547,829 | 5,137,141 |
| Female | 81,607 | 24.1 | 874,265 | 0.1 | 3 | 63,569 | 18.8 | 662,059 | 0.2 | 5 | 338,051 | 3,220,004 |
| Disabled | 8,742 | 23.9 | 100,547 | 0.1 | 4 | 17,674 | 48.3 | 196,951 | 0.3 | 12 | 36,619 | 365,894 |
| 5 and younger | 1,500 | 66.2 | 17,031 | 0.2 | 4 | 281 | 12.4 | 3,201 | 0.1 | 1 | 2,267 | 22,710 |
| 6-14 | 1,697 | 42.4 | 19,817 | 0.1 | 4 | 603 | 15.1 | 6,998 | 0.1 | 2 | 3,998 | 43,142 |
| 15-20 | 1,010 | 33.7 | 11,750 | 0.1 | 4 | 1,101 | 36.7 | 12,650 | 0.2 | 3 | 3,000 | 31,679 |
| 21-44 | 2,546 | 21.4 | 29,268 | 0.1 | 3 | 7,411 | 62.4 | 83,055 | 0.3 | 11 | 11,872 | 118,642 |
| 45-64 | 1,925 | 13.4 | 21,919 | 0.1 | 4 | 8,037 | 55.9 | 88,248 | 0.3 | 16 | 14,382 | 137,284 |
| 65-74 | 55 | 7.3 | 654 | 0.1 | 3 | 208 | 27.7 | 2,413 | 0.3 | 13 | 752 | 8,508 |
| 75-84 | 9 | 3.7 | 108 | 0.1 | 1 | 32 | 13.1 | 374 | 0.4 | 8 | 244 | 2,748 |
| 85 and older | 0 | 0.0 | 0 | 0.0 | 0 | 1 | 1.0 | 12 | 0.5 | 89 | 104 | 1,181 |
| Other Eligibles | 72,865 | 24.2 | 773,718 | 0.1 | 3 | 45,895 | 15.2 | 465,108 | 0.2 | 3 | 301,432 | 2,854,110 |
| 5 and younger | 33,279 | 51.7 | 348,538 | 0.1 | 3 | 3,769 | 5.9 | 41,462 | 0.1 | 1 | 64,323 | 569,903 |
| 6-14 | 23,201 | 31.5 | 256,323 | 0.1 | 3 | 7,580 | 10.3 | 84,255 | 0.1 | 1 | 73,547 | 716,875 |
| 15-20 | 8,788 | 16.6 | 94,126 | 0.1 | 3 | 12,264 | 23.1 | 127,511 | 0.1 | 2 | 53,070 | 491,039 |
| 21-44 | 7,254 | 6.9 | 71,270 | 0.1 | 3 | 21,055 | 20.0 | 200,029 | 0.2 | 4 | 105,345 | 1,028,949 |
| 45-64 | 223 | 7.5 | 2,212 | 0.1 | 3 | 746 | 25.0 | 6,744 | 0.3 | 9 | 2,989 | 26,323 |
| 65-74 | 34 | 8.1 | 377 | 0.1 | 4 | 146 | 34.6 | 1,591 | 0.4 | 19 | 422 | 3,968 |
| 75-84 | 45 | 6.3 | 472 | 0.1 | 5 | 192 | 26.8 | 2,020 | 0.4 | 18 | 717 | 6,864 |
| 85 and older | 41 | 4.0 | 400 | 0.1 | 2 | 143 | 14.0 | 1,496 | 0.4 | 12 | 1,019 | 10,189 |
| Male | 70,772 | 33.8 | 756,905 | 0.1 | 4 | 27,559 | 13.2 | 294,943 | 0.2 | 5 | 209,086 | 1,911,768 |
| Disabled | 8,105 | 23.2 | 92,916 | 0.1 | 4 | 9,105 | 26.0 | 98,381 | 0.3 | 12 | 34,980 | 334,570 |
| 5 and younger | 2,203 | 64.5 | 25,188 | 0.2 | 5 | 449 | 13.1 | 5,131 | 0.1 | 1 | 3,417 | 33,631 |
| 6-14 | 2,878 | 37.2 | 33,383 | 0.1 | 4 | 975 | 12.6 | 11,367 | 0.1 | 2 | 7,737 | 82,031 |
| 15-20 | 1,070 | 22.9 | 12,357 | 0.1 | 4 | 1,059 | 22.7 | 12,060 | 0.1 | 3 | 4,674 | 48,226 |
| 21-44 | 1,153 | 11.7 | 13,175 | 0.1 | 5 | 3,140 | 32.0 | 33,751 | 0.3 | 13 | 9,816 | 91,358 |
| 45-64 | 764 | 8.7 | 8,383 | 0.1 | 5 | 3,389 | 38.5 | 35,013 | 0.4 | 21 | 8,796 | 73,493 |
| 65-74 | 34 | 8.8 | 394 | 0.1 | 4 | 84 | 21.6 | 955 | 0.3 | 10 | 388 | 4,159 |
| 75-84 | 3 | 2.8 | 36 | 0.1 | 3 | 9 | 8.3 | 104 | 0.2 | 4 | 108 | 1,150 |
| 85 and older | 0 | 0.0 | 0 | 0.0 | 0 | 0 | 0.0 | 0 | 0.0 | 0 | 44 | 522 |
| Other Eligibles | 62,667 | 36.0 | 663,989 | 0.1 | 3 | 18,454 | 10.6 | 196,562 | 0.1 | 2 | 174,106 | 1,577,198 |
| 5 and younger | 36,531 | 53.7 | 378,411 | 0.1 | 4 | 4,641 | 6.8 | 50,400 | 0.1 | 1 | 68,025 | 593,750 |
| 6-14 | 21,282 | 28.3 | 234,090 | 0.1 | 3 | 7,538 | 10.0 | 82,970 | 0.1 | 1 | 75,135 | 717,264 |
| 15-20 | 4,521 | 16.9 | 48,431 | 0.1 | 3 | 4,870 | 18.2 | 51,695 | 0.1 | 2 | 26,732 | 239,218 |
| 21-44 | 213 | 8.3 | 1,870 | 0.1 | 4 | 906 | 35.2 | 6,872 | 0.3 | 16 | 2,577 | 13,605 |
| 45-64 | 30 | 5.5 | 257 | 0.2 | 4 | 228 | 41.8 | 1,841 | 0.4 | 23 | 545 | 3,048 |
| 65-74 | 38 | 11.3 | 412 | 0.1 | 5 | 95 | 28.4 | 946 | 0.3 | 14 | 335 | 2,969 |
| 75-84 | 30 | 7.9 | 301 | 0.2 | 6 | 104 | 27.2 | 1,103 | 0.3 | 13 | 382 | 3,610 |
| 85 and older | 22 | 5.9 | 217 | 0.1 | 4 | 72 | 19.2 | 735 | 0.2 | 5 | 375 | 3,734 |
| Unknown | 215 | 31.1 | 2,285 | 0.1 | 4 | 78 | 11.3 | 798 | 0.2 | 3 | 692 | 5,369 |

Table ND7D

Nondual Beneficiaries

Source: Data for this table are from the MAX 2002 file for Arkansas, released by CMS in 05/2006. This table was produced on 04/19/2007.

- a. Table ND.7D includes the beneficiaries represented by Cell K of Table 1. A user is a beneficiary who had at least one prescription filled in a given drug group during 2002. A beneficiary who used drugs from two or more drug groups was counted as a user for each group. Therefore, the sum of users across drug groups may exceed the total number of individual users. Benefit months are months during which beneficiaries had fee-for-service pharmacy benefits.
- b. Medicaid reimbursement amounts presented in this table do not reflect federally required rebates from drug manufacturers to the state.
- c. The top 10 drug groups were determined based on total Medicaid reimbursement in the state for 2002. For information about these drug groups, see Wolters Kluwer Health, http://www.Medi-Span.com/products/product_mddb.asp (May 13 2003).

Bene(s) = beneficiary (or beneficiaries); Bene Mo(s) = benefit month(s); BOE = basis of eligibility; CMS = Center for Medicare and Medicaid Services; MAX = Medicaid Analytic Extract; Rx = prescription(s) or pharmacy; \$ = Medicaid reimbursement.

TABLE ND.8
 MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT FOR ALL-YEAR NURSING FACILITY RESIDENTS,
 BY BENEFICIARY CHARACTERISTIC^{a, b}
 NONDUAL BENEFICIARIES, ARKANSAS, 2002

| Beneficiary Characteristics | Rx \$ per Bene Mo | No. of Rx per Bene Mo | No. of All-Year NF Residents | Bene Mos among All-Year NF Residents |
|-----------------------------------------|-------------------|-----------------------|------------------------------|--------------------------------------|
| All | \$340 | 6.2 | 1,372 | 13,855 |
| Age | | | | |
| 0-64 | 391 | 6.5 | 698 | 7,186 |
| 65-74 | 327 | 6.1 | 175 | 1,828 |
| 75-84 | 302 | 6.5 | 234 | 2,294 |
| 85 and older | 238 | 5.4 | 265 | 2,547 |
| Unknown | 0 | 0.0 | 0 | 0 |
| Gender | | | | |
| Female | 353 | 6.6 | 800 | 8,272 |
| Male | 321 | 5.7 | 561 | 5,468 |
| Unknown | 282 | 6.6 | 11 | 115 |
| Race | | | | |
| White | 340 | 6.4 | 965 | 9,628 |
| African American | 333 | 5.8 | 370 | 3,828 |
| Other/unknown | 389 | 5.9 | 37 | 399 |
| Basis of Eligibility^c | | | | |
| Aged | 285 | 6.1 | 600 | 5,829 |
| Disabled | 379 | 6.3 | 772 | 8,026 |
| Adults | 0 | 0.0 | 0 | 0 |
| Children | 0 | 0.0 | 0 | 0 |
| Unknown | 0 | 0.0 | 0 | 0 |

Source: Data for this table are from the MAX 2002 file for Arkansas, released by CMS in 05/2006. This table was produced on 04/19/2007.

a. Table ND.8 includes the beneficiaries represented by Cell L of Table 1, those who resided in nursing facilities throughout their 2002 Medicaid enrollment. A total of 515 beneficiaries who were in nursing facilities for part of their enrollment and their 4,892 benefit months were excluded from the analysis. Benefit months are months during which beneficiaries had fee-for-service pharmacy benefits.

b. Medicaid reimbursement amounts presented in this table do not reflect federally required rebates from drug manufacturers to the state.

c. Medicaid basis of eligibility is classified as: aged, disabled, adults, and children. The disabled group includes beneficiaries of any age who were determined to be eligible because of disability or blindness. The children's group includes children receiving foster care and adoptive services.

Bene(s) = beneficiary (or beneficiaries); Bene Mo(s) = benefit month(s); CMS = Center for Medicare and Medicaid Services; MAX = Medicaid Analytic Extract; NF = nursing facility; Rx = prescription(s) or pharmacy; \$ = Medicaid reimbursement.

TABLE ND.9
 MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT FOR ALL-YEAR NURSING FACILITY RESIDENTS,
 BY BRAND STATUS AND THERAPEUTIC CATEGORY^{a, b, c, d, e}
 NONDUAL BENEFICIARIES, ARKANSAS, 2002

| Therapeutic Category | No. of Rx per Bene Mo among Users | | | \$ per Bene Mo among Users | | | Total # of Rx | Total Rx \$ | No. | As % of All-Year NF Residents | No. of Bene Mos | | | | | | |
|-------------------------------------------------|-----------------------------------|------------|------------|----------------------------|------------|------------|---------------|-------------|------|-------------------------------|-----------------|---------|---------|-----------|------|--------|--------|
| | Patented | | | Patented | | | | | | | | Generic | Generic | Generic | | | |
| | Total | Off-Patent | Brand-Name | Total | Off-Patent | Brand-Name | | | | | | | | | | | |
| Anti-infective Agents | 0.4 | 0.2 | 0.0 | 0.2 | \$24 | \$20 | \$1 | \$3 | \$60 | \$100 | \$72 | \$16 | 3,637 | \$219,364 | 859 | 62.6 % | 9,171 |
| Biologicals | 0.0 | 0.0 | 0.0 | 0.0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0.0 | 0 |
| Antineoplastic Agents | 0.5 | 0.1 | 0.0 | 0.4 | 86 | 40 | 11 | 35 | 163 | 338 | 248 | 95 | 578 | 94,370 | 107 | 7.8 | 1,099 |
| Endocrine/Metabolic Drugs | 1.2 | 0.6 | 0.2 | 0.4 | 52 | 40 | 6 | 6 | 45 | 65 | 36 | 17 | 7,290 | 326,820 | 584 | 42.6 | 6,234 |
| Cardiovascular Agents | 2.1 | 0.5 | 0.2 | 1.4 | 57 | 30 | 5 | 22 | 27 | 58 | 28 | 15 | 19,117 | 506,682 | 876 | 63.8 | 8,924 |
| Respiratory Agents | 0.7 | 0.3 | 0.0 | 0.3 | 31 | 20 | 3 | 8 | 46 | 70 | 59 | 23 | 3,618 | 166,564 | 513 | 37.4 | 5,456 |
| Gastrointestinal Agents | 1.0 | 0.3 | 0.0 | 0.7 | 44 | 32 | 1 | 12 | 44 | 103 | 56 | 17 | 7,130 | 311,806 | 677 | 49.3 | 7,049 |
| Genitourinary Agents | 0.7 | 0.4 | 0.0 | 0.2 | 38 | 33 | 0 | 4 | 57 | 75 | 41 | 20 | 2,149 | 121,941 | 303 | 22.1 | 3,204 |
| CNS Drugs | 1.7 | 0.9 | 0.1 | 0.7 | 156 | 132 | 6 | 18 | 91 | 142 | 71 | 25 | 17,397 | 1,582,865 | 970 | 70.7 | 10,146 |
| Stimulants/Anti-obesity/Anorexia | 0.6 | 0.0 | 0.0 | 0.6 | 12 | 0 | 0 | 12 | 21 | 0 | 0 | 21 | 30 | 634 | 6 | 0.4 | 51 |
| Miscellaneous Psychological/Neurological Agents | 0.8 | 0.8 | 0.0 | 0.0 | 107 | 107 | 0 | 0 | 127 | 127 | 0 | 0 | 1,068 | 135,856 | 127 | 9.3 | 1,264 |
| Analgesics and Anesthetics | 0.8 | 0.2 | 0.0 | 0.5 | 38 | 28 | 2 | 8 | 46 | 115 | 47 | 15 | 5,496 | 252,548 | 638 | 46.5 | 6,663 |
| Neuromuscular Agents | 1.4 | 0.6 | 0.1 | 0.7 | 88 | 61 | 8 | 19 | 64 | 111 | 54 | 28 | 8,669 | 551,329 | 580 | 42.3 | 6,238 |
| Nutritional Products | 0.8 | 0.0 | 0.0 | 0.7 | 14 | 0 | 1 | 13 | 18 | 11 | 22 | 17 | 3,344 | 58,671 | 420 | 30.6 | 4,318 |
| Hematological Agents | 1.0 | 0.3 | 0.2 | 0.5 | 63 | 54 | 2 | 8 | 64 | 185 | 10 | 15 | 3,952 | 251,070 | 396 | 28.9 | 3,962 |
| Topical Products | 0.4 | 0.2 | 0.0 | 0.2 | 17 | 12 | 2 | 4 | 44 | 68 | 66 | 18 | 2,649 | 115,526 | 622 | 45.3 | 6,719 |
| Miscellaneous Products | 0.2 | 0.0 | 0.0 | 0.2 | 5 | 1 | 0 | 4 | 20 | 58 | 0 | 17 | 110 | 2,239 | 46 | 3.4 | 477 |
| Unknown Therapeutic Category | 0.3 | 0.0 | 0.0 | 0.0 | 8 | 0 | 0 | 0 | 22 | 0 | 0 | 0 | 230 | 5,056 | 60 | 4.4 | 659 |
| TOTAL NO. OF RX AND RX \$ | n.a. | n.a. | n.a. | n.a. | n.a. | n.a. | n.a. | n.a. | n.a. | n.a. | n.a. | n.a. | 86,464 | 4,703,341 | n.a. | n.a. | n.a. |

Source: Data for this table are from the MAX 2002 file for Arkansas, released by CMS in 05/2006. This table was produced on 04/19/2007.

a. Table ND.9 includes the beneficiaries represented by Cell L of Table 1, those who resided in nursing facilities throughout their Medicaid enrollment in 2002. A total of 515 beneficiaries who were in nursing facilities for part of their enrollment and their 4,892 benefit months were excluded from the analysis.

b. A user is a beneficiary who had at least one prescription filled in a given therapeutic category during 2002. A beneficiary who used drugs from two or more categories was counted as a user for each category. Therefore, the sum of users across categories may exceed the total number of individual users. Benefit months are months during which beneficiaries had fee-for-service pharmacy benefits.

c. Medicaid reimbursement amounts presented in this table do not reflect federally required rebates from drug manufacturers to the state.

d. For information about these therapeutic categories, see Wolters Kluwer Health, http://www.Medi-Span.com/products/product_mddb.asp (May 13 2003).

e. Brand-name drugs, sometimes called "innovator single-source drugs," are drugs whose patents have not yet expired. Off-patent brand-name drugs, sometimes called "innovator multiple-source drugs," are brand-name drugs whose patents have expired. Generic drugs, sometimes called "non-innovator multiple-source drugs," are off-patent drugs manufactured and sold by companies other than the original patent holder. For information about this classification method, see Wolters Kluwer Health, http://www.Medi-Span.com/products/product_mddb.asp (May 13 2003).

In Arkansas, 0.2 percent of drug claims have missing values for brand status. Thus, the sum of the three groups in this table may be smaller than all prescriptions combined.

Bene Mo(s) = benefit month(s); CMS = Center for Medicare and Medicaid Services; CNS = Central Nervous System; MAX = Medicaid Analytic Extract; n.a. = not applicable; NF = nursing facility; Rx = prescription(s) or pharmacy benefit; \$ = Medicaid reimbursement.

TABLE ND.10
 MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT FOR TOP 10 DRUG GROUPS AMONG ALL-YEAR NURSING FACILITY RESIDENTS,
 BY TOP-10 DRUG GROUP^{a, b, c, d}
 NONDUAL BENEFICIARIES, ARKANSAS, 2002

| Top 10 Drug Groups in Nursing Facilities | Users | | | | Among Users | | |
|------------------------------------------|----------------------|--------------|-------------------------------|-----------------|-----------------------|-------------|-------------------|
| | Total Medicaid Rx \$ | No. of Users | As % of All-Year NF Residents | No. of Bene Mos | No. of Rx per Bene Mo | \$ per Rx | Rx \$ per Bene Mo |
| ANTIPSYCHOTICS | \$1,088,639 | 758 | 55.2 % | 8,478 | 0.8 | \$157 | \$128 |
| ANTICONVULSANT | 442,689 | 592 | 43.1 | 6,479 | 1.0 | 70 | 68 |
| ANTIDEPRESSANTS | 397,933 | 741 | 54.0 | 7,877 | 0.8 | 60 | 51 |
| ULCER DRUGS | 259,731 | 756 | 55.1 | 8,180 | 0.6 | 51 | 32 |
| ANTI-DIABETIC | 178,722 | 376 | 27.4 | 4,223 | 0.7 | 56 | 42 |
| ANTI-HYPERTENSIVE | 136,960 | 506 | 36.9 | 5,311 | 0.8 | 31 | 26 |
| MISC PSYCHOTHERAPEUTIC AND NEUROLOGICAL | 135,856 | 120 | 8.7 | 1,231 | 0.9 | 127 | 110 |
| ANALGESICS - Narcotic | 127,531 | 639 | 46.6 | 6,702 | 0.5 | 42 | 19 |
| CALCIUM BLOCKERS | 120,244 | 280 | 20.4 | 2,959 | 0.9 | 44 | 41 |
| ANTI-ASTHMATIC | 112,776 | 418 | 30.5 | 4,405 | 0.5 | 54 | 26 |
| Total | 3,001,081 | 5,186 | | 55,845 | n.a. | n.a. | n.a. |

Source: Data for this table are from the MAX 2002 file for Arkansas, released by CMS in 05/2006. This table was produced on 04/19/2007.

a. Table ND.10 includes the beneficiaries represented by Cell L of Table 1, those who resided in nursing facilities throughout their Medicaid enrollment in 2002. A total of 515 beneficiaries who were in nursing facilities for part of their enrollment and their 4,892 benefit months were excluded from the analysis.

b. A user is a beneficiary who had at least one prescription filled in a given drug group during 2002. A beneficiary who used drugs from two or more drug groups was counted as a user for each group. Therefore, the sum of users across drug groups may exceed the total number of individual users. Benefit months are months during which beneficiaries had fee-for-service pharmacy benefits.

c. Medicaid reimbursement amounts presented in this table do not reflect federally required rebates from drug manufacturers to the state.

d. The top 10 drug groups were determined based on total 2002 Medicaid reimbursement for all-year nursing facility residents in this state. For information about these drug groups, see Wolters Kluwer Health, http://www.Medi-Span.com/products/product_mdmb.asp (May 13 2003).

Bene Mo(s) = benefit month(s); CMS = Center for Medicare and Medicaid Services; MAX = Medicaid Analytic Extract; NF = nursing facility; Rx = prescription(s) or pharmacy benefit; \$ = Medicaid reimbursement.

TABLE ND.10A

MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT PER BENEFIT MONTH FOR TOP 10 DRUG GROUPS COMBINED AND FIRST AND SECOND TOP DRUG GROUPS SEPARATELY AMONG ALL-YEAR NURSING FACILITY RESIDENTS, BY SEX, BOE, AND AGE^{a, b, c, d} NONDUAL BENEFICIARIES, ARKANSAS, 2002

| Beneficiary Characteristics | All Top 10 Drug Groups | | | | | | | | | | ANTIPSYCHOTICS | | | | | ANTICONVULSANT | | | | |
|-----------------------------|------------------------|--------------------|--------------|-----------------------------|--------------|----------------|--------------|--------------|-----------------------------|--------------|----------------|-------------|--------------|-----------------------------|--------------|----------------|------------|--|--|--|
| | No. of Rx | Rx \$ | Users as % | | | Mean No. of Rx | Mean Rx \$ | Users as % | | | Mean No. of Rx | Mean Rx \$ | Users as % | | | Mean No. of Rx | Mean Rx \$ | | | |
| | | | No. of Users | No. of Bene Mos among Users | NF Residents | | | No. of Users | No. of Bene Mos among Users | NF Residents | | | No. of Users | No. of Bene Mos among Users | NF Residents | | | | | |
| All | 41,486 | \$3,001,081 | 758 | 55.2 % | 8,478 | 0.8 | \$128 | 592 | 43.1 % | 6,479 | 1.0 | \$68 | | | | | | | | |
| Female | 25,913 | 1,905,807 | 468 | 58.5 | 5,187 | 0.9 | 135 | 360 | 45.0 | 3,994 | 1.0 | 69 | | | | | | | | |
| Disabled | 15,214 | 1,239,782 | 297 | 71.2 | 3,430 | 0.9 | 155 | 260 | 62.4 | 2,955 | 1.0 | 74 | | | | | | | | |
| 64 or younger | 13,865 | 1,140,389 | 265 | 71.2 | 3,049 | 0.9 | 158 | 233 | 62.6 | 2,663 | 1.0 | 76 | | | | | | | | |
| 65-74 | 856 | 62,903 | 25 | 80.6 | 297 | 0.8 | 114 | 16 | 51.6 | 171 | 0.8 | 40 | | | | | | | | |
| 75-84 | 460 | 34,621 | 7 | 53.8 | 84 | 0.9 | 158 | 10 | 76.9 | 109 | 0.9 | 74 | | | | | | | | |
| 85 and older | 33 | 1,869 | 0 | 0.0 | 0 | 0.0 | 0 | 1 | 100.0 | 12 | 0.8 | 71 | | | | | | | | |
| Other Eligibles | 10,699 | 666,025 | 171 | 44.6 | 1,757 | 0.7 | 98 | 100 | 26.1 | 1,039 | 0.9 | 54 | | | | | | | | |
| 64 or younger | 0 | 0 | 0 | 0.0 | 0 | 0.0 | 0 | 0 | 0.0 | 0 | 0.0 | 0 | | | | | | | | |
| 65-74 | 1,887 | 116,263 | 39 | 70.9 | 397 | 0.8 | 91 | 27 | 49.1 | 285 | 1.0 | 60 | | | | | | | | |
| 75-84 | 4,586 | 284,576 | 63 | 42.9 | 650 | 0.8 | 109 | 39 | 26.5 | 400 | 0.9 | 48 | | | | | | | | |
| 85 and older | 4,226 | 265,186 | 69 | 38.1 | 710 | 0.7 | 92 | 34 | 18.8 | 354 | 0.9 | 57 | | | | | | | | |
| Male | 15,252 | 1,075,075 | 284 | 50.6 | 3,225 | 0.8 | 117 | 228 | 40.6 | 2,437 | 1.0 | 68 | | | | | | | | |
| Disabled | 10,122 | 747,870 | 181 | 51.1 | 2,083 | 0.8 | 132 | 177 | 50.0 | 1,914 | 1.0 | 73 | | | | | | | | |
| 64 or younger | 9,359 | 679,916 | 163 | 50.2 | 1,872 | 0.8 | 132 | 165 | 50.8 | 1,790 | 1.0 | 74 | | | | | | | | |
| 65-74 | 635 | 54,249 | 16 | 64.0 | 187 | 0.8 | 124 | 10 | 40.0 | 105 | 1.0 | 61 | | | | | | | | |
| 75-84 | 128 | 13,705 | 2 | 50.0 | 24 | 1.5 | 243 | 2 | 50.0 | 19 | 0.7 | 16 | | | | | | | | |
| 85 and older | 0 | 0 | 0 | 0.0 | 0 | 0.0 | 0 | 0 | 0.0 | 0 | 0.0 | 0 | | | | | | | | |
| Other Eligibles | 5,130 | 327,205 | 103 | 49.8 | 1,142 | 0.6 | 90 | 51 | 24.6 | 523 | 1.0 | 51 | | | | | | | | |
| 64 or younger | 0 | 0 | 0 | 0.0 | 0 | 0.0 | 0 | 0 | 0.0 | 0 | 0.0 | 0 | | | | | | | | |
| 65-74 | 2,103 | 154,092 | 51 | 82.3 | 574 | 0.7 | 104 | 28 | 45.2 | 312 | 1.0 | 55 | | | | | | | | |
| 75-84 | 1,715 | 95,824 | 23 | 34.3 | 259 | 0.7 | 82 | 16 | 23.9 | 155 | 1.0 | 46 | | | | | | | | |
| 85 and older | 1,312 | 77,289 | 29 | 37.2 | 309 | 0.6 | 70 | 7 | 9.0 | 56 | 0.8 | 46 | | | | | | | | |
| Unknown | 321 | 20,199 | 6 | 54.5 | 66 | 0.5 | 121 | 4 | 36.4 | 48 | 0.6 | 17 | | | | | | | | |

Source: Data for this table are from the MAX 2002 file for Arkansas, released by CMS in 05/2006. This table was produced on 04/19/2007.

a. Table ND.10A includes the beneficiaries represented by Cell L of Table 1, those who resided in nursing facilities throughout their Medicaid enrollment in 2002. A total of 515 beneficiaries who were in nursing facilities for part of their enrollment and their 4,892 benefit months were excluded from the analysis.

b. A user is a beneficiary who had at least one prescription filled in a given drug group during 2002. A beneficiary who used drugs from two or more drug groups was counted as a user for each group. Therefore, the sum of users across drug groups may exceed the total number of individual users. Benefit months are months during which beneficiaries had fee-for-service pharmacy benefits.

c. Medicaid reimbursement amounts presented in this table do not reflect federally required rebates from drug manufacturers to the state.

d. The top 10 drug groups were determined based on total 2002 Medicaid reimbursement for all-year nursing facility residents in this state. For information about these drug groups, see Wolters Kluwer Health, http://www.Medi-Span.com/products/product_mddb.asp (May 13 2003).

Bene Mo(s) = benefit month(s); BOE = basis of eligibility; CMS = Center for Medicare and Medicaid Services; MAX = Medicaid Analytic Extract; NF = nursing facility; Rx = prescription(s) or pharmacy benefit; \$ = Medicaid reimbursement.

TABLE ND.10B
 MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT PER BENEFIT MONTH FOR THIRD TO FIFTH TOP DRUG GROUPS SEPARATELY
 AMONG ALL-YEAR NURSING FACILITY RESIDENTS, BY SEX, BOE, AND AGE^{a, b, c, d}
 NONDUAL BENEFICIARIES, ARKANSAS, 2002

| Beneficiary Characteristics | ANTIDEPRESSANTS | | | | | | ULCER DRUGS | | | | | | ANTIDIABETIC | | | | | | |
|-----------------------------|-----------------|-----------------------------|----------------|-------------|--------------|----------------|-----------------------------|----------------|-------------|--------------|----------------|-----------------------------|----------------|-------------|--------------|----------------|-----------------------------|----------------|------------|
| | Users as % | | | Users as % | | | Users as % | | | Users as % | | | Users as % | | | Users as % | | | |
| | No. of Users | No. of Bene Mos among Users | Mean No. of Rx | Mean Rx \$ | No. of Users | Mean No. of Rx | No. of Bene Mos among Users | Mean No. of Rx | Mean Rx \$ | No. of Users | Mean No. of Rx | No. of Bene Mos among Users | Mean No. of Rx | Mean Rx \$ | No. of Users | Mean No. of Rx | No. of Bene Mos among Users | Mean No. of Rx | Mean Rx \$ |
| All | 741 | 54.0 % | 0.8 | \$51 | 756 | 55.1 % | 8,180 | 0.6 | \$32 | 376 | 27.4 % | 4,223 | 0.7 | \$42 | | | | | |
| Female | | | | | | | | | | | | | | | | | | | |
| Disabled | | | | | | | | | | | | | | | | | | | |
| 64 or younger | 257 | 61.6 | 0.9 | 51 | 208 | 49.9 | 2,278 | 0.6 | 33 | 151 | 36.2 | 1,717 | 0.8 | 47 | | | | | |
| 65-74 | 11 | 35.5 | 0.9 | 49 | 13 | 41.9 | 146 | 0.7 | 33 | 14 | 45.2 | 159 | 0.7 | 22 | | | | | |
| 75-84 | 5 | 38.5 | 0.7 | 45 | 2 | 15.4 | 24 | 0.7 | 77 | 9 | 69.2 | 108 | 0.8 | 37 | | | | | |
| 85 and older | 1 | 100.0 | 0.9 | 69 | 1 | 100.0 | 12 | 0.9 | 14 | 0 | 0.0 | 0 | 0.0 | 0 | | | | | |
| Other Eligibles | | | | | | | | | | | | | | | | | | | |
| 64 or younger | 224 | 58.5 | 0.8 | 51 | 231 | 60.3 | 2,475 | 0.6 | 32 | 88 | 23.0 | 1,002 | 0.7 | 35 | | | | | |
| 65-74 | 44 | 80.0 | 0.8 | 51 | 34 | 61.8 | 360 | 0.6 | 25 | 12 | 21.8 | 126 | 0.8 | 40 | | | | | |
| 75-84 | 84 | 57.1 | 0.8 | 51 | 93 | 63.3 | 995 | 0.6 | 30 | 50 | 34.0 | 585 | 0.7 | 35 | | | | | |
| 85 and older | 96 | 53.0 | 0.8 | 51 | 104 | 57.5 | 1,120 | 0.6 | 35 | 26 | 14.4 | 291 | 0.7 | 33 | | | | | |
| Male | | | | | | | | | | | | | | | | | | | |
| Disabled | | | | | | | | | | | | | | | | | | | |
| 64 or younger | 151 | 42.7 | 0.9 | 54 | 193 | 54.5 | 2,089 | 0.7 | 34 | 89 | 25.1 | 967 | 0.7 | 42 | | | | | |
| 65-74 | 6 | 24.0 | 0.9 | 73 | 16 | 64.0 | 182 | 0.7 | 39 | 9 | 36.0 | 108 | 0.8 | 65 | | | | | |
| 75-84 | 3 | 75.0 | 0.7 | 51 | 2 | 50.0 | 24 | 1.0 | 151 | 1 | 25.0 | 12 | 1.0 | 16 | | | | | |
| 85 and older | 0 | 0.0 | 0.0 | 0 | 0 | 0.0 | 0 | 0.0 | 0 | 0 | 0.0 | 0 | 0.0 | 0 | | | | | |
| Other Eligibles | | | | | | | | | | | | | | | | | | | |
| 64 or younger | 99 | 47.8 | 0.8 | 45 | 117 | 56.5 | 1,254 | 0.6 | 27 | 48 | 23.2 | 537 | 0.7 | 41 | | | | | |
| 65-74 | 36 | 58.1 | 0.8 | 46 | 46 | 74.2 | 507 | 0.5 | 33 | 19 | 30.6 | 218 | 0.7 | 50 | | | | | |
| 75-84 | 29 | 43.3 | 0.9 | 45 | 40 | 59.7 | 422 | 0.6 | 20 | 18 | 26.9 | 196 | 0.6 | 35 | | | | | |
| 85 and older | 34 | 43.6 | 0.7 | 43 | 31 | 39.7 | 325 | 0.6 | 27 | 11 | 14.1 | 123 | 0.9 | 32 | | | | | |
| Unknown | 10 | 90.9 | 0.7 | 33 | 7 | 63.6 | 84 | 0.5 | 18 | 0 | 0.0 | 0 | 0.0 | 0 | | | | | |

Source: Data for this table are from the MAX 2002 file for Arkansas, released by CMS in 05/2006. This table was produced on 04/19/2007.

a. Table ND.10B includes the beneficiaries represented by Cell L of Table 1, those who resided in nursing facilities throughout their Medicaid enrollment in 2002. A total of 515 beneficiaries who were in nursing facilities for part of their enrollment and their 4,892 benefit months were excluded from the analysis.

b. A user is a beneficiary who had at least one prescription filled in a given drug group during 2002. A beneficiary who used drugs from two or more drug groups was counted as a user for each group. Therefore, the sum of users across drug groups may exceed the total number of individual users. Benefit months are months during which beneficiaries had fee-for-service pharmacy benefits.

c. Medicaid reimbursement amounts presented in this table do not reflect federally required rebates from drug manufacturers to the state.

d. The top 10 drug groups were determined based on total 2002 Medicaid reimbursement for all-year nursing facility residents in this state. For information about these drug groups, see Wolters Kluwer Health, http://www.Medi-Span.com/products/product_mddb.asp (May 13 2003).

Bene Mo(s) = benefit month(s); BOE = basis of eligibility; CMS = Center for Medicare and Medicaid Services; MAX = Medicaid Analytic Extract; NF = nursing facility; Rx = prescription(s) or pharmacy benefit; \$ = Medicaid reimbursement.

TABLE ND.10C
 MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT PER BENEFIT MONTH FOR SIXTH TO EIGHTH TOP DRUG GROUPS SEPARATELY
 AMONG ALL-YEAR NURSING FACILITY RESIDENTS, BY SEX, BOE, AND AGE^{a, b, c, d}
 NONDUAL BENEFICIARIES, ARKANSAS, 2002

| Beneficiary Characteristics | ANTIHYPERTENSIVE | | | | | MISC PSYCHOTHERAPEUTIC AND NEUROLOGICAL | | | | | ANALGESICS - Narcotic | | | | | | |
|-----------------------------|------------------|-------------------------|----------------|-------------|----------------|-----------------------------------------|-------------------------|----------------|------------|----------------|-----------------------|-------------------------|----------------|------------|--------------|-------------------------|----------------|
| | Users as % | | | | | Users as % | | | | | Users as % | | | | | | |
| | No. of Users | No. of Bene among Users | Mean No. of Rx | Mean Rx \$ | Mean No. of Rx | No. of Users | No. of Bene among Users | Mean No. of Rx | Mean Rx \$ | Mean No. of Rx | No. of Users | No. of Bene among Users | Mean No. of Rx | Mean Rx \$ | No. of Users | No. of Bene among Users | Mean No. of Rx |
| All | 506 | 36.9 % | 0.8 | \$26 | 0.8 | 120 | 8.7 % | 1,231 | 0.9 | \$110 | 639 | 46.6 % | 6,702 | 0.5 | \$19 | | |
| Female | 298 | 37.3 | 0.8 | 26 | 0.8 | 77 | 9.6 | 782 | 0.9 | 115 | 380 | 47.5 | 4,033 | 0.5 | 20 | | |
| Disabled | 144 | 34.5 | 0.8 | 28 | 0.8 | 19 | 4.6 | 199 | 0.9 | 118 | 194 | 46.5 | 2,054 | 0.5 | 26 | | |
| 64 or younger | 126 | 33.9 | 0.8 | 29 | 0.8 | 17 | 4.6 | 175 | 1.0 | 126 | 177 | 47.6 | 1,870 | 0.6 | 26 | | |
| 65-74 | 10 | 32.3 | 0.8 | 19 | 0.8 | 0 | 0.0 | 0 | 0.0 | 0 | 11 | 35.5 | 112 | 0.3 | 30 | | |
| 75-84 | 8 | 61.5 | 0.8 | 22 | 0.8 | 2 | 15.4 | 24 | 0.5 | 59 | 6 | 46.2 | 72 | 0.4 | 11 | | |
| 85 and older | 0 | 0.0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0 | 0.0 | 0 | 0.0 | 0 | | |
| Other Eligibles | 154 | 40.2 | 0.8 | 24 | 0.8 | 58 | 15.1 | 583 | 0.9 | 114 | 186 | 48.6 | 1,979 | 0.4 | 14 | | |
| 64 or younger | 0 | 0.0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0 | 0.0 | 0 | 0.0 | 0 | | |
| 65-74 | 24 | 43.6 | 0.8 | 20 | 0.8 | 7 | 12.7 | 65 | 0.9 | 124 | 37 | 67.3 | 419 | 0.5 | 10 | | |
| 75-84 | 75 | 51.0 | 0.9 | 26 | 0.9 | 25 | 17.0 | 251 | 1.0 | 122 | 64 | 43.5 | 677 | 0.5 | 18 | | |
| 85 and older | 55 | 30.4 | 0.8 | 22 | 0.8 | 26 | 14.4 | 267 | 0.8 | 104 | 85 | 47.0 | 883 | 0.4 | 13 | | |
| Male | 201 | 35.8 | 0.8 | 26 | 0.8 | 41 | 7.3 | 431 | 0.8 | 102 | 254 | 45.3 | 2,620 | 0.4 | 18 | | |
| Disabled | 117 | 33.1 | 0.8 | 28 | 0.8 | 9 | 2.5 | 90 | 0.9 | 123 | 152 | 42.9 | 1,508 | 0.5 | 22 | | |
| 64 or younger | 112 | 34.5 | 0.8 | 28 | 0.8 | 9 | 2.8 | 90 | 0.9 | 123 | 144 | 44.3 | 1,417 | 0.5 | 23 | | |
| 65-74 | 4 | 16.0 | 0.9 | 31 | 0.9 | 0 | 0.0 | 0 | 0.0 | 0 | 8 | 32.0 | 91 | 0.2 | 6 | | |
| 75-84 | 1 | 25.0 | 1.0 | 74 | 1.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0 | 0.0 | 0 | 0.0 | 0 | | |
| 85 and older | 0 | 0.0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0 | 0.0 | 0 | 0.0 | 0 | | |
| Other Eligibles | 84 | 40.6 | 0.8 | 22 | 0.8 | 32 | 15.5 | 341 | 0.8 | 97 | 102 | 49.3 | 1,112 | 0.3 | 12 | | |
| 64 or younger | 0 | 0.0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0 | 0.0 | 0 | 0.0 | 0 | | |
| 65-74 | 28 | 45.2 | 0.8 | 21 | 0.8 | 10 | 16.1 | 108 | 0.6 | 82 | 35 | 56.5 | 397 | 0.4 | 17 | | |
| 75-84 | 32 | 47.8 | 0.8 | 25 | 0.8 | 11 | 16.4 | 111 | 0.8 | 98 | 31 | 46.3 | 341 | 0.3 | 17 | | |
| 85 and older | 24 | 30.8 | 0.8 | 21 | 0.8 | 11 | 14.1 | 122 | 0.9 | 110 | 36 | 46.2 | 374 | 0.2 | 3 | | |
| Unknown | 7 | 63.6 | 0.8 | 24 | 0.8 | 2 | 18.2 | 18 | 0.8 | 104 | 5 | 45.5 | 49 | 0.4 | 10 | | |

Source: Data for this table are from the MAX 2002 file for Arkansas, released by CMS in 05/2006. This table was produced on 04/19/2007.

a. Table ND.10C includes the beneficiaries represented by Cell L of Table 1, those who resided in nursing facilities throughout their Medicaid enrollment in 2002. A total of 515 beneficiaries who were in nursing facilities for part of their enrollment and their 4,892 benefit months were excluded from the analysis.

b. A user is a beneficiary who had at least one prescription filled in a given drug group during 2002. A beneficiary who used drugs from two or more drug groups was counted as a user for each group. Therefore, the sum of users across drug groups may exceed the total number of individual users. Benefit months are months during which beneficiaries had fee-for-service pharmacy benefits.

c. Medicaid reimbursement amounts presented in this table do not reflect federally required rebates from drug manufacturers to the state.

d. The top 10 drug groups were determined based on total 2002 Medicaid reimbursement for all-year nursing facility residents in this state. For information about these drug groups, see Wolters Kluwer Health, http://www.Medi-Span.com/products/product_mddb.asp (May 13 2003).

Benefit Mo(s) = benefit month(s); BOE = basis of eligibility; CMS = Center for Medicare and Medicaid Services; MAX = Medicaid Analytic Extract; NF = nursing facility; Rx = prescription(s) or pharmacy benefit; \$ = Medicaid reimbursement.

TABLE ND.10D
 MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT PER BENEFIT MONTH FOR NINTH AND TENTH TOP DRUG GROUPS
 SEPARATELY AMONG ALL-YEAR NURSING FACILITY RESIDENTS, BY SEX, BOE, AND AGE^{a, b, c, d}
 NONDUAL BENEFICIARIES, ARKANSAS, 2002

| Beneficiary Characteristics | CALCIUM BLOCKERS | | | | | ANTIASTHMATIC | | | | | Bene Mos among All-Year NF Residents | | |
|-----------------------------|------------------|-----------------------------|------------------|-----------------------------|------------|------------------|-----------------------------|------------------|--------------|------------|--------------------------------------|--------------|---------------|
| | Users as % | | Users as % | | Mean Rx \$ | Users as % | | Users as % | | Mean Rx \$ | | | |
| | No. of Users | No. of Bene Mos among Users | No. of Residents | No. of Bene Mos among Users | | No. of Residents | No. of Bene Mos among Users | No. of Residents | | | | | |
| All | 280 | 20.4 % | 2,959 | 0.9 | 0.9 | \$41 | 418 | 30.5 % | 4,405 | 0.5 | \$26 | 1,372 | 13,855 |
| Female | 164 | 20.5 | 1,714 | 0.9 | 0.9 | 40 | 252 | 31.5 | 2,659 | 0.5 | 28 | 800 | 8,272 |
| Disabled | 67 | 16.1 | 735 | 0.9 | 0.9 | 42 | 130 | 31.2 | 1,452 | 0.5 | 28 | 417 | 4,571 |
| 64 or younger | 63 | 16.9 | 690 | 0.9 | 0.9 | 43 | 120 | 32.3 | 1,332 | 0.5 | 29 | 372 | 4,058 |
| 65-74 | 4 | 12.9 | 45 | 0.6 | 0.6 | 18 | 5 | 16.1 | 60 | 0.5 | 30 | 31 | 356 |
| 75-84 | 0 | 0.0 | 0 | 0.0 | 0.0 | 0 | 4 | 30.8 | 48 | 0.4 | 10 | 13 | 145 |
| 85 and older | 0 | 0.0 | 0 | 0.0 | 0.0 | 0 | 1 | 100.0 | 12 | 0.1 | 1 | 1 | 12 |
| Other Eligibles | 97 | 25.3 | 979 | 0.9 | 0.9 | 38 | 122 | 31.9 | 1,207 | 0.5 | 29 | 383 | 3,701 |
| 64 or younger | 0 | 0.0 | 0 | 0.0 | 0.0 | 0 | 0 | 0.0 | 0 | 0.0 | 0 | 0 | 0 |
| 65-74 | 9 | 16.4 | 87 | 0.9 | 0.9 | 40 | 15 | 27.3 | 153 | 0.6 | 32 | 55 | 526 |
| 75-84 | 40 | 27.2 | 412 | 1.0 | 1.0 | 42 | 53 | 36.1 | 486 | 0.7 | 37 | 147 | 1,416 |
| 85 and older | 48 | 26.5 | 480 | 0.9 | 0.9 | 35 | 54 | 29.8 | 568 | 0.4 | 20 | 181 | 1,759 |
| Male | 112 | 20.0 | 1,197 | 0.9 | 0.9 | 42 | 161 | 28.7 | 1,686 | 0.4 | 22 | 561 | 5,468 |
| Disabled | 73 | 20.6 | 781 | 1.0 | 1.0 | 44 | 85 | 24.0 | 885 | 0.5 | 26 | 354 | 3,443 |
| 64 or younger | 68 | 20.9 | 726 | 1.0 | 1.0 | 43 | 81 | 24.9 | 837 | 0.5 | 25 | 325 | 3,116 |
| 65-74 | 4 | 16.0 | 43 | 0.7 | 0.7 | 42 | 4 | 16.0 | 48 | 0.5 | 40 | 25 | 284 |
| 75-84 | 1 | 25.0 | 12 | 1.0 | 1.0 | 115 | 0 | 0.0 | 0 | 0.0 | 0 | 4 | 43 |
| 85 and older | 0 | 0.0 | 0 | 0.0 | 0.0 | 0 | 0 | 0.0 | 0 | 0.0 | 0 | 0 | 0 |
| Other Eligibles | 39 | 18.8 | 416 | 0.8 | 0.8 | 38 | 76 | 36.7 | 801 | 0.4 | 19 | 207 | 2,025 |
| 64 or younger | 0 | 0.0 | 0 | 0.0 | 0.0 | 0 | 0 | 0.0 | 0 | 0.0 | 0 | 0 | 0 |
| 65-74 | 13 | 21.0 | 137 | 0.9 | 0.9 | 55 | 24 | 38.7 | 266 | 0.3 | 11 | 62 | 638 |
| 75-84 | 13 | 19.4 | 142 | 0.8 | 0.8 | 30 | 38 | 56.7 | 374 | 0.5 | 29 | 67 | 665 |
| 85 and older | 13 | 16.7 | 137 | 0.8 | 0.8 | 29 | 14 | 17.9 | 161 | 0.2 | 8 | 78 | 722 |
| Unknown | 4 | 36.4 | 48 | 0.7 | 0.7 | 33 | 5 | 45.5 | 60 | 0.4 | 9 | 11 | 115 |

Source: Data for this table are from the MAX 2002 file for Arkansas, released by CMS in 05/2006. This table was produced on 04/19/2007.

a. Table ND.10D includes the beneficiaries represented by Cell L of Table 1, those who resided in nursing facilities throughout their Medicaid enrollment in 2002. A total of 515 beneficiaries who were in nursing facilities for part of their enrollment and their 4,892 benefit months were excluded from the analysis.

b. A user is a beneficiary who had at least one prescription filled in a given drug group during 2002. A beneficiary who used drugs from two or more drug groups was counted as a user for each group. Therefore, the sum of users across drug groups may exceed the total number of individual users. Benefit months are months during which beneficiaries had fee-for-service pharmacy benefits.

c. Medicaid reimbursement amounts presented in this table do not reflect federally required rebates from drug manufacturers to the state.

d. The top 10 drug groups were determined based on total 2002 Medicaid reimbursement for all-year nursing facility residents in this state. For information about these drug groups, see Wolters Kluwer Health, http://www.Medi-Span.com/products/product_mddb.asp (May 13 2003).

Bene Mo(s) = benefit month(s); BOE = basis of eligibility; CMS = Center for Medicare and Medicaid Services; MAX = Medicaid Analytic Extract; NF = nursing facility; Rx = prescription(s) or pharmacy benefit; \$ = Medicaid reimbursement.

TABLE ND.11
 USE AND REIMBURSEMENT FOR DRUGS EXCLUDED BY STATUTE FROM MEDICARE PART D
 AMONG NONDUALS, BY BENEFICIARY CHARACTERISTIC^{a,b}
 ARKANSAS, 2002

| Beneficiary Characteristics | No. of Benes with at Least One Part D Excl Rx | % Benes with at Least One Part D Excl Rx | No. of Part D Excl Rx per Bene | Total No. Part D Excl Rx | Part D Excl Rx \$ per Bene | Total Part D Excl Rx \$ | \$ per Part D Excl Rx | Part D Excl Rx \$ as % of All Nondual Rx \$ | Total No. of Benes |
|----------------------------------------------|-----------------------------------------------|------------------------------------------|--------------------------------|--------------------------|----------------------------|-------------------------|-----------------------|---------------------------------------------|--------------------|
| | | | | | | | | | |
| Age | | | | | | | | | |
| 5 and younger | 55,184 | 39.9 | 1.0 | 132,917 | 12 | 1,657,357 | 12 | 6.6 | 138,293 |
| 6-14 | 39,841 | 24.8 | 0.5 | 78,686 | 9 | 1,374,951 | 17 | 3.3 | 160,648 |
| 15-20 | 14,132 | 16.1 | 0.3 | 29,624 | 8 | 704,878 | 24 | 3.5 | 87,551 |
| 21-44 | 11,936 | 9.2 | 0.3 | 42,742 | 8 | 988,468 | 23 | 2.9 | 129,660 |
| 45-64 | 6,867 | 25.7 | 1.5 | 40,893 | 35 | 926,205 | 23 | 2.8 | 26,735 |
| 65-74 | 434 | 22.7 | 1.4 | 2,772 | 29 | 56,289 | 20 | 2.7 | 1,915 |
| 75-84 | 328 | 22.4 | 1.5 | 2,178 | 27 | 40,139 | 18 | 2.8 | 1,464 |
| 85 and older | 239 | 15.4 | 1.2 | 1,793 | 20 | 30,906 | 17 | 3.3 | 1,551 |
| Unknown | 0 | 0.0 | 0.0 | 0 | 0 | 0 | 0 | 0.0 | 12 |
| Basis of Eligibility^c | | | | | | | | | |
| Aged | 726 | 22.2 | 1.5 | 4,895 | 27 | 88,071 | 18 | 2.8 | 3,268 |
| Disabled | 20,060 | 28.0 | 1.4 | 97,386 | 33 | 2,393,281 | 25 | 2.7 | 71,634 |
| Adults | 11,099 | 7.7 | 0.2 | 25,422 | 4 | 512,989 | 20 | 4.0 | 144,972 |
| Children | 97,076 | 29.6 | 0.6 | 203,902 | 8 | 2,784,852 | 14 | 5.2 | 327,955 |
| Unknown | 0 | 0.0 | 0.0 | 0 | 0 | 0 | 0 | 0.0 | 0 |
| Gender | | | | | | | | | |
| Female | 71,231 | 21.1 | 0.6 | 187,990 | 10 | 3,343,453 | 18 | 3.9 | 338,054 |
| Male | 57,563 | 27.5 | 0.7 | 143,228 | 12 | 2,430,329 | 17 | 3.3 | 209,095 |
| Unknown | 167 | 24.6 | 0.6 | 387 | 8 | 5,411 | 14 | 3.1 | 680 |
| Race | | | | | | | | | |
| White | 79,723 | 23.9 | 0.6 | 208,393 | 12 | 3,970,457 | 19 | 3.8 | 333,435 |
| African American | 40,667 | 22.8 | 0.6 | 99,406 | 8 | 1,359,076 | 14 | 3.4 | 178,657 |
| Other/unknown | 8,571 | 24.0 | 0.7 | 23,806 | 13 | 449,660 | 19 | 3.3 | 35,737 |
| Use of Nursing Facilities^d | | | | | | | | | |
| Entire year | 730 | 53.2 | 5.1 | 6,989 | 89 | 121,961 | 17 | 2.6 | 1,372 |
| Part year | 300 | 58.3 | 3.7 | 1,909 | 130 | 66,949 | 35 | 5.0 | 515 |
| None | 127,931 | 23.4 | 0.6 | 322,707 | 10 | 5,590,283 | 17 | 3.7 | 545,942 |
| Maintenance Assistance Status | | | | | | | | | |
| Cash | 33,830 | 27.4 | 1.0 | 128,046 | 21 | 2,640,430 | 21 | 2.9 | 123,261 |
| Medically needy | 1,794 | 18.1 | 0.5 | 4,837 | 10 | 97,301 | 20 | 3.4 | 9,919 |
| Poverty related | 68,438 | 29.8 | 0.6 | 143,937 | 9 | 2,053,530 | 14 | 5.8 | 229,791 |
| Other/unknown | 24,899 | 13.5 | 0.3 | 54,785 | 5 | 987,932 | 18 | 3.5 | 184,858 |

Table ND11

Nondual Beneficiaries

Source: Data for this table are from the MAX 2002 file for Arkansas, released by CMS in 05/2006. This table was produced on 04/19/2007.

- a. Table ND.11 includes the beneficiaries represented by Cell K of Table 1. Beneficiaries include all nondual Medicaid beneficiaries who had Medicaid pharmacy benefits during at least one month in 2002.
- b. The statute establishing the Medicare Part D prescription program that started in 2006 excludes several types of drugs from coverage. State Medicaid programs have been allowed to exclude these drugs since 1990, but many states have chosen to cover them, and if states cover them for any Medicaid beneficiaries they must also cover them for dual eligibles, who as of 2006 receive the remainder of their prescription drug coverage through Part D. Excluded drugs include benzodiazepines; barbiturates; nonprescription (OTC) medications; prescription vitamins and minerals (not including prenatal vitamins and fluoride preparations); and drugs used for anorexia, weight loss, or weight gain. Other excluded drugs include those that promote fertility; those used for cosmetic purposes or hair growth, for symptomatic relief of coughs and colds; or drugs for which the manufacturer requires that associated tests or monitoring services be purchased exclusively from the manufacturer.
- c. Medicaid basis of eligibility is classified as: aged, disabled, adults, and children. The disabled group includes beneficiaries of any age who were determined to be eligible because of disability or blindness. The children's group includes children receiving foster care and adoptive services.
- d. Please refer to footnote f on Table 1 for methodology used to determine use of nursing facilities.
- Bene(s) = beneficiary (or beneficiaries); CMS = Center for Medicare and Medicaid Services; Excl = excluded; MAX = Medicaid Analytic Extract; OTC = over-the-counter; Rx = prescription(s) or pharmacy benefit; \$ = Medicaid reimbursement.

TABLE ND.12

USE AND REIMBURSEMENT FOR DRUGS EXCLUDED BY STATUTE FROM MEDICARE PART D
 AMONG NONDUALS PER BENEFIT MONTH, BY BENEFICIARY CHARACTERISTIC^{a,b}
 ARKANSAS, 2002

| Beneficiary Characteristics | No. Rx per Bene Mo. | Rx \$ per Bene Mo. | \$ per Rx | Barbiturate \$ per Bene Mo. | Benzodiazepine \$ per Bene Mo. | No. of Bene Mos |
|----------------------------------------------|---------------------|--------------------|-----------|-----------------------------|--------------------------------|-----------------|
| All | 0.1 | \$1 | \$17 | \$0 | \$0 | 5,137,141 |
| Age | | | | | | |
| 5 and younger | 0.1 | 1 | 12 | 0 | 0 | 1,221,941 |
| 6-14 | 0.1 | 1 | 17 | 0 | 0 | 1,561,255 |
| 15-20 | 0.0 | 1 | 24 | 0 | 0 | 810,801 |
| 21-44 | 0.0 | 1 | 23 | 0 | 0 | 1,252,858 |
| 45-64 | 0.2 | 4 | 23 | 0 | 2 | 240,301 |
| 65-74 | 0.1 | 3 | 20 | 0 | 1 | 19,743 |
| 75-84 | 0.2 | 3 | 18 | 0 | 1 | 14,488 |
| 85 and older | 0.1 | 2 | 17 | 0 | 1 | 15,726 |
| Unknown | 0.0 | 0 | 0 | 0 | 0 | 28 |
| Basis of Eligibility^c | | | | | | |
| Aged | 0.2 | 3 | 18 | 0 | 1 | 31,530 |
| Disabled | 0.1 | 3 | 25 | 0 | 2 | 700,752 |
| Adults | 0.0 | 0 | 20 | 0 | 0 | 1,374,779 |
| Children | 0.1 | 1 | 14 | 0 | 0 | 3,030,080 |
| Unknown | 0.0 | 0 | 0 | 0 | 0 | 0 |
| Gender | | | | | | |
| Female | 0.1 | 1 | 18 | 0 | 0 | 3,220,013 |
| Male | 0.1 | 1 | 17 | 0 | 0 | 1,911,787 |
| Unknown | 0.1 | 1 | 14 | 0 | 0 | 5,341 |
| Race | | | | | | |
| White | 0.1 | 1 | 19 | 0 | 0 | 3,134,948 |
| African American | 0.1 | 1 | 14 | 0 | 0 | 1,690,626 |
| Other/unknown | 0.1 | 1 | 19 | 0 | 0 | 311,567 |
| Use of Nursing Facilities^d | | | | | | |
| Entire year | 0.5 | 9 | 17 | 0 | 4 | 13,855 |
| Part year | 0.4 | 14 | 35 | 0 | 4 | 4,892 |
| None | 0.1 | 1 | 17 | 0 | 0 | 5,118,394 |
| Maintenance Assistance Status | | | | | | |
| Cash | 0.1 | 2 | 21 | 0 | 1 | 1,172,881 |
| Medically needy | 0.1 | 2 | 20 | 0 | 1 | 53,094 |
| Poverty related | 0.1 | 1 | 14 | 0 | 0 | 2,045,655 |
| Other/unknown | 0.0 | 1 | 18 | 0 | 0 | 1,865,511 |

Source: Data for this table are from the MAX 2002 file for Arkansas, released by CMS in 05/2006. This table was produced on 04/19/2007.

- a. Table ND.12 includes the beneficiaries represented by Cell K of Table 1. Benefit months are months during which beneficiaries had fee-for-service pharmacy benefits. Beneficiaries include all nondual Medicaid beneficiaries who had Medicaid pharmacy benefits during at least one month in 2002.
 - b. The statute establishing the Medicare Part D prescription program that started in 2006 excludes several types of drugs from coverage. State Medicaid programs have been allowed to exclude these drugs since 1990, but many states have chosen to cover them, and if states cover them for any Medicaid beneficiaries they must also cover them for dual eligibles, who as of 2006 receive the remainder of their prescription drug coverage through Part D. Excluded drugs include benzodiazepines; barbiturates; nonprescription (OTC) medications; prescription vitamins and minerals (not including prenatal vitamins and fluoride preparations); and drugs used for anorexia, weight loss, or weight gain. Other excluded drugs include those that promote fertility; those used for cosmetic purposes or hair growth, for symptomatic relief of coughs and colds; or drugs for which the manufacturer requires that associated tests or monitoring services be purchased exclusively from the manufacturer.
 - c. Medicaid basis of eligibility is classified as: aged, disabled, adults, and children. The disabled group includes beneficiaries of any age who were determined to be eligible because of disability or blindness. The children's group includes children receiving foster care and adoptive services.
 - d. Please refer to footnote f on Table 1 for methodology used to determine use of nursing facilities.
- Bene(s) = beneficiary (or beneficiaries); CMS = Center for Medicare and Medicaid Services; Excl = excluded; MAX = Medicaid Analytic Extract; OTC = over-the-counter; Rx = prescription(s) or pharmacy benefit; \$ = Medicaid reimbursement.

TABLE ND.13
 USE AND REIMBURSEMENT FOR DRUGS EXCLUDED BY STATUTE FROM MEDICARE PART D
 FOR SELECTED DRUG CATEGORIES AMONG NONDUALS^{a,b,c}
 ARKANSAS, 2002

| Drug Category | No. Users | Rx \$ per User | Total Rx \$ | Rx \$ as % of All Part D Excl Rx \$ | Total No. Rx. | \$ per Rx | No. Rx as % of All Part D Excl Rx |
|------------------------------|----------------|----------------|--------------------|-------------------------------------|----------------|-------------|-----------------------------------|
| All | 147,989 | \$39 | \$5,779,193 | 100.0 % | 331,605 | \$17 | 100.0 % |
| Anorexia or weight loss/gain | 0 | 0 | 0 | 0.0 | 0 | 0 | 0.0 |
| Fertility drugs | 2 | 34 | 67 | 0.0 | 2 | 34 | 0.0 |
| Drugs for cosmetic purposes | 30 | 15 | 435 | 0.0 | 38 | 11 | 0.0 |
| Cough and cold medications | 93,851 | 29 | 2,719,445 | 47.1 | 183,329 | 15 | 55.3 |
| Vitamins and minerals | 4,661 | 112 | 520,778 | 9.0 | 21,594 | 24 | 6.5 |
| Non-prescription drugs | 32,019 | 14 | 434,611 | 7.5 | 50,738 | 9 | 15.3 |
| Barbiturates | 1,140 | 52 | 59,162 | 1.0 | 7,771 | 8 | 2.3 |
| Benzodiazepines | 13,430 | 110 | 1,475,733 | 25.5 | 62,349 | 24 | 18.8 |
| Other Part D Excl Rx Drugs | 2,856 | 199 | 568,962 | 9.8 | 5,784 | 98 | 1.7 |

Source: Data for this table are from the MAX 2002 file for Arkansas, released by CMS in 05/2006. This table was produced on 04/19/2007.

- a. Table ND.13 includes the beneficiaries represented by Cell K of Table 1. Beneficiaries include all nondual Medicaid beneficiaries who had Medicaid pharmacy benefits during at least one month in 2002. A user is a beneficiary who had at least one prescription filled for a Part D excluded drug in 2002. A beneficiary who used drugs from two or more Part D excluded categories was counted as a user for each category. Therefore, the sum of users across drug categories may exceed the total number of individual users as noted on Table ND11.
- b. Includes OTC drugs as well as prescription drugs.
- c. The statute establishing the Medicare Part D prescription program that started in 2006 excludes several types of drugs from coverage. State Medicaid programs have been allowed to exclude these drugs since 1990, but many states have chosen to cover them, and if states cover them for any Medicaid beneficiaries they must also cover them for dual eligibles, who as of 2006 receive the remainder of their prescription drug coverage through Part D. Excluded drugs include benzodiazepines; barbiturates; nonprescription (OTC) medications; prescription vitamins and minerals (not including prenatal vitamins and fluoride preparations); and drugs used for anorexia, weight loss, or weight gain. Other excluded drugs include those that promote fertility; those used for cosmetic purposes or hair growth, for symptomatic relief of coughs and colds; or drugs for which the manufacturer requires that associated tests or monitoring services be purchased exclusively from the manufacturer.
- Bene(s) = beneficiary (or beneficiaries); CMS = Center for Medicare and Medicaid Services; Excl = excluded; MAX = Medicaid Analytic Extract; OTC = over-the-counter; Rx = prescription(s) or pharmacy benefit; \$ = Medicaid reimbursement.

APPENDIX TABLE A.1

CHARACTERISTICS OF MEDICAID BENEFICIARIES WITH AT LEAST ONE MONTH OF PHARMACY BENEFIT COVERAGE, BY BASIS OF ELIGIBILITY^{a, b}
NONDUAL BENEFICIARIES, ARKANSAS, 2002

| Beneficiary Characteristics | No. of Beneficiaries | | | | | No. of Beneficiaries by Status | | | | | | |
|----------------------------------------------|----------------------|--------------|---------------|----------------|----------------|--------------------------------|------------------|---------------|----------------|------------------|------------------|----------|
| | All | Aged | Disabled | Adults | Children | Unknown | All | Aged | Disabled | Adults | Children | Unknown |
| All | 547,829 | 3,268 | 71,634 | 144,972 | 327,955 | 0 | 5,137,141 | 31,530 | 700,752 | 1,374,779 | 3,030,080 | 0 |
| Age | | | | | | | | | | | | |
| 5 and younger | 138,293 | 0 | 5,686 | 71 | 132,536 | 0 | 1,221,941 | 0 | 56,356 | 508 | 1,165,077 | 0 |
| 6-14 | 160,648 | 0 | 11,735 | 197 | 148,716 | 0 | 1,561,255 | 0 | 125,173 | 1,489 | 1,434,593 | 0 |
| 15-20 | 87,551 | 0 | 7,674 | 33,582 | 46,295 | 0 | 810,801 | 0 | 79,905 | 301,803 | 429,093 | 0 |
| 21-44 | 129,660 | 0 | 21,693 | 107,573 | 394 | 0 | 1,252,858 | 0 | 210,049 | 1,041,537 | 1,272 | 0 |
| 45-64 | 26,735 | 0 | 23,196 | 3,537 | 2 | 0 | 240,301 | 0 | 210,911 | 29,373 | 17 | 0 |
| 65-74 | 1,915 | 758 | 1,148 | 9 | 0 | 0 | 19,743 | 6,968 | 12,733 | 42 | 0 | 0 |
| 75-84 | 1,464 | 1,109 | 353 | 2 | 0 | 0 | 14,488 | 10,554 | 3,910 | 24 | 0 | 0 |
| 85 and older | 1,551 | 1,401 | 149 | 1 | 0 | 0 | 15,726 | 14,008 | 1,715 | 3 | 0 | 0 |
| Unknown | 12 | 0 | 0 | 0 | 12 | 0 | 28 | 0 | 0 | 0 | 28 | 0 |
| Gender | | | | | | | | | | | | |
| Female | 338,054 | 2,151 | 36,619 | 137,732 | 161,552 | 0 | 3,220,013 | 20,968 | 365,894 | 1,323,098 | 1,510,053 | 0 |
| Male | 209,095 | 1,087 | 34,980 | 7,176 | 165,852 | 0 | 1,911,787 | 10,297 | 334,570 | 51,293 | 1,515,627 | 0 |
| Unknown | 680 | 30 | 35 | 64 | 551 | 0 | 5,341 | 265 | 288 | 388 | 4,400 | 0 |
| Race | | | | | | | | | | | | |
| White | 333,435 | 2,000 | 39,655 | 94,653 | 197,127 | 0 | 3,134,948 | 18,961 | 382,072 | 909,129 | 1,824,786 | 0 |
| African American | 178,657 | 984 | 23,211 | 46,003 | 108,459 | 0 | 1,690,626 | 9,632 | 236,648 | 432,635 | 1,011,711 | 0 |
| Other/unknown | 35,737 | 284 | 8,768 | 4,316 | 22,369 | 0 | 311,567 | 2,937 | 82,032 | 33,015 | 193,583 | 0 |
| Use of Nursing Facilities^c | | | | | | | | | | | | |
| Entire year | 1,372 | 600 | 772 | 0 | 0 | 0 | 13,855 | 5,829 | 8,026 | 0 | 0 | 0 |
| Part year | 515 | 175 | 338 | 2 | 0 | 0 | 4,892 | 1,526 | 3,351 | 15 | 0 | 0 |
| None | 545,942 | 2,493 | 70,524 | 144,970 | 327,955 | 0 | 5,118,394 | 24,175 | 689,375 | 1,374,764 | 3,030,080 | 0 |
| Maintenance Assistance Status | | | | | | | | | | | | |
| Cash | 123,261 | 1,373 | 63,363 | 20,766 | 37,759 | 0 | 1,172,881 | 15,634 | 633,773 | 171,557 | 351,917 | 0 |
| Medically needy | 9,919 | 113 | 2,314 | 4,869 | 2,623 | 0 | 53,094 | 397 | 9,046 | 24,293 | 19,358 | 0 |
| Poverty related | 229,791 | 136 | 542 | 28,271 | 200,842 | 0 | 2,045,655 | 974 | 4,223 | 198,041 | 1,842,417 | 0 |
| Other/unknown | 184,858 | 1,646 | 5,415 | 91,066 | 86,731 | 0 | 1,865,511 | 14,525 | 53,710 | 980,888 | 816,388 | 0 |
| Managed Care Status | | | | | | | | | | | | |
| FFS all year | 547,829 | 3,268 | 71,634 | 144,972 | 327,955 | 0 | 5,137,141 | 31,530 | 700,752 | 1,374,779 | 3,030,080 | 0 |
| FFS part year, with Rx claims | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| FFS part year, no Rx claims | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| MC all year, with Rx claims | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| MC all year, no Rx claims | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |

Source: Data for this table are from the MAX 2002 file for Arkansas, released by CMS in 05/2006. This table was produced on 04/19/2007.

a. Table A.1 includes the beneficiaries represented by Cell J of Table 1. Benefit months are months during which beneficiaries had pharmacy benefit coverage.

b. Medicaid basis of eligibility is classified as: aged, disabled, adults, and children. The disabled group includes beneficiaries of any age who were determined to be eligible because of disability or blindness. The children's group includes children receiving foster care and adoptive services. The total includes some beneficiaries with unknown basis of eligibility and some whose age categories are not consistent with basis of eligibility.

c. Please refer to footnote f of Table 1 for methodology used to determine nursing facility residence.

Bene Mo(s) = beneficiary (or beneficiaries); Bene Mo(s) = benefit month(s); CMS = Center for Medicare and Medicaid Services; FFS = fee-for-service pharmacy benefit; MAX = Medicaid Analytic Extract; MC = managed care; Rx = pharmacy benefit.

APPENDIX TABLE A.2
 MEDICAID BENEFICIARIES AND THEIR BENEFIT MONTHS WITH OR WITHOUT FEE-FOR-SERVICE PHARMACY BENEFITS^a
 NONDUAL BENEFICIARIES, ARKANSAS, 2002

| | Bene Mos in Cell J of Table 1 | | Included in Cell K of Table 1 | | Excluded from Cell K of Table 1 | |
|----------------------------------|-------------------------------|------------------|-------------------------------|------------------|---------------------------------|-----------------|
| | No. of Benes | No. of Bene Mos | No. of Benes | No. of Bene Mos | No. of Benes | No. of Bene Mos |
| All | 547,829 | 5,137,141 | 547,829 | 5,137,141 | 0 | 0 |
| FFS all year | 547,829 | 5,137,141 | 547,829 | 5,137,141 | 0 | 0 |
| FFS part year, with Rx claims | 0 | 0 | 0 | 0 | 0 | 0 |
| FFS part year, with no Rx claims | 0 | 0 | 0 | 0 | 0 | 0 |
| MC all year, with Rx claims | 0 | 0 | 0 | 0 | 0 | 0 |
| MC all year, with no Rx claims | 0 | 0 | 0 | 0 | 0 | 0 |

Source: Data for this table are from the MAX 2002 file for Arkansas, released by CMS in 05/2006. This table was produced on 04/19/2007.

a. Benefit months are months during which beneficiaries had pharmacy benefit coverage.

Bene(s) = beneficiary (or beneficiaries); Bene Mo(s) = benefit month(s); CMS = Center for Medicare and Medicaid Services; FFS = fee-for-service pharmacy benefit; MAX = Medicaid Analytic Extract; MC = managed care; Rx = pharmacy benefit.